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Covering: 1947-early 2017, particularly from 2005-early 2017 
 
The rise of bacterial pathogens with acquired resistance to almost all available antibiotics is becoming a serious public 
health issue. Polymyxins, antibiotics that were mostly abandoned a few decades ago because of toxicity concerns, are 
ultimately considered as a last-line therapy to treat infections caused by multi-drug resistant Gram-negative bacteria. This 
review surveys the progress in understanding polymyxin structure, chemistry, mechanisms of antibacterial activity and 
nephrotoxicity, biomarkers, synergy and combination with other antimicrobial agents and antibiofilm properties. An 
update of recent efforts in the design and development of a new generation of polymyxin drugs is also discussed. A novel 
approach considering the modification of the scaffold of polymyxins to integrate metabolism and detoxification issues into 
the drug design process is a promising new line to potentially prevent accumulation in kidney and reduce nephrotoxicity. 
 
1.  Introduction 
2.  Naturally ocurring polymyxins 
3.  Antimicrobial profile  
4.  Commercially available polymyxins 
5.  Mechanism of action 
6.  Resistance to polymyxins 
7.  Combination with other antibiotics 
8.  Synergy with antifungals 
9.  Antibiofilm activity 
10. Toxicity 
10.1. Mechanism of nephrotoxicity 
10.2  Biomarkers of nephrotoxicity 
11.  Design and development of new polymyxins 
11.1  Synthetic preparation of polymyxin analogs 
11.2  CB-182,804 analog 
11.3  Pfizer 5x analog 
11.4  Monash FADDI analogs 
11.5  Queensland analogs 
11.6  Northern Antibiotics analogs 
11.7  Cantab analogs 
11.8  Scaffold modified polymyxins 
11.9  MicuRx analogs 
11.10 Barcelona analogs 
12.  Conclusions and perspectives 
13. Acknowledgements 
14.  References 
1. Introduction 
Polymyxins are a group of antimicrobial cyclic lipopeptides 
discovered in 1947.
1-3
 They are produced by fermentation of strains 
of Paenibacillus polymyxa (formerly known as Bacillus polymyxa). 
Polymyxins consist of a heterogeneous mixture composed of up to 
30 closely related lipopeptides (Table I).
4-7
 The term “polymyxin” is 
accepted as the general name for this class of antibiotics produced 
by P. polymyxa. Polymyxin B and colistin (polymyxin E) are the most 
known members of this family as they were commonly used as 
antibiotics in hospitals from late 1950s to late 1970s, 
approximately. Then, they were gradually withdrawn from the 
clinical practice due to toxicity issues such as adverse neurological 
effects and most importantly, nephrotoxicity concerns. In addition, 
novel aminoglycosides (gentamicin) and second- and third-
generation cephalosporins showing less toxic side effects became 
available.
8
 However, the emergence of Gram-negative bacteria that 
are resistant to almost all classes of available antibiotics has 
resulted in the rescue of polymyxins as a last resort for patients 
whose other treatment options were limited.  
Antibiotic resistance is becoming a serious public health issue. 
In the USA, for instance, at least 2 million people are infected by 
antibiotic-resistant bacteria and at least 23,000 people die each 
year as a direct consequence.9,10  A similar situation is taking place 
in Europe.
 11,12
  The WHO has recently issued a list of the most 
critical pathogenic bacteria for which new antibiotics are urgently 
needed:  carbapenem-resistant strains of Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacteriaceae.
13
  
Polymyxin B and colistin are now used as a last-line therapy to 
treat infections caused by multi-drug resistant bacteria such as P. 
aeruginosa, A. baumannii, Klebsiella pneumoniae, and Escherichia 
coli . These bacteria are part of the so-called ESKAPE bacteria, thus 
nicknamed by the Infectious Disease Society of America that  
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Table 1: Structure of naturally occurring polymyxins B and E 
(colistin), clinically relevant members of the polymyxin family§ 
Polymyxin Fatty acyl tail Aa 6 Aa7 
B1 (S)-6-methyloctanoyl D-Phe Leu 
B1-Ile (S)-6-methyloctanoyl D-Phe Ile 
B2 6-methyheptanoyl D-Phe Leu 
B3 octanoyl D-Phe Leu 
B4 heptanoyl D-Phe Leu 
B5 nonanoyl D-Phe Leu 
B6 3-hydroxy-6-methyloctanoyl D-Phe Leu 
E1 (S)-6-methyloctanoyl D-Leu Leu 
E2 6-methyheptanoyl D-Leu Leu 
E3 octanoyl D-Leu Leu 
E4 heptanoyl D-Leu Leu 
E7 7-methyloctanoyl D-Leu Leu 
E1-Ile 
(circulin A) 
(S)-6-methyloctanoyl D-Leu Ile 
E1-Val (S)-6-methyloctanoyl D-Leu Val 
E1-Nva (S)-6-methyloctanoyl D-Leu Nva 
E2-Val 6-methyheptanoyl D-Leu Val 
E2-Ile 6-methyheptanoyl D-Leu Ile 
E8-Ile 7-methylnonanoyl D-Leu Ile 
 
Table 2: Structure of additional naturally occurring polymyxins§  
Polymyxin Fatty acyl tail Aa3 Aa6 Aa7 Aa10 
A1 6-methyloctanoyl D-Dab D-Leu Thr Thr 
A2 6-methylheptanoyl D-Dab D-Leu Thr Thr 
C1 6-methyloctanoyl Dab Phe Thr Thr 
C2 6-methylheptanoyl Dab Phe Thr Thr 
D1 6-methyloctanoyl D-Ser D-Leu Thr Thr 
D2 6-methylheptanoyl D-Ser D-Leu Thr Thr 
F1 6-methyloctanoyl (Dab x5, Thr, Leu x2, Ser, Ile) 
F2 6-methylheptanoyl (Dab x5, Thr, Leu x2, Ser, Ile) 
M1 6-methyloctanoyl Dab D-Leu Thr Thr 
M2 6-methylheptanoyl Dab D-Leu Thr Thr 
S1 6-methyloctanoyl  D-Ser D-Phe Thr Thr 
T1 6-methyloctanoyl Dab D-Phe Leu Leu 
T2 6-methylheptanoyl Dab D-Phe Leu Leu 
PMB1 6-methyloctanoyl D-Dab D-Phe Thr Thr 
PMB2 6-methylheptanoyl D-Dab D-Phe Thr Thr 
P1 6-methyloctanoyl  D-Dab D-Phe Thr Thr 
P2 6-methylheptanoyl  D-Dab D-Phe Thr Thr 
§ The reader may find nomenclatures such as "iso" and  "ante-iso" fatty 
acids in the literature. For instance, isooctanoic acid, i-C8 corresponds to  
6-methylheptanoic acid. Anteisononanoic acid, a-C9, corresponds to 6-
methyloctanoic acid and may appear in two different configurations, R or S, 
since a stereocenter is present in carbon 6. The configuration of this 
stereocenter is expected to be S as the branch-chain fatty acid synthesizing 
system starts in the case of anteiso-fatty acids from the α-ketoacid of 
isoleucine as primer. Isoleucine has an S configuration in carbon 3, in its 
sidechain. 
 
has proposed to pursue a global commitment to develop 10 new 
antibacterial drugs by 2020 (the 10 x '20 Initiative).  “ESKAPE” 
stands for the initials of the above mentioned Gram-negative 





Figure 1: Polymyxin B1 as an example of the general structure of 
polymyxins. Amino acid positions are numbered from 1 to 10. 
 
The objective of this review is to gather and analyze the 
background in the field of polymyxins, highlighting  the efforts and 
new approaches carried out by different groups worldwide toward 
the design and development of new polymyxin-based compounds 
potentially capable of overcoming the current drawbacks of the 
natural compound, particularly, nephrotoxicity. Other fundamental 
reviews in the field of polymyxins have been published in the last 
years. As the present manuscript will mainly but not only 
concentrate in the last decade achievements and new approaches, 
the reader is also addressed to reviews by Vaara, Velkov&Li, 
Brown&Dawson for a previous background in the area.
14-17
  
2. Naturally occuring polymyxins 
The Paenibacillus genus (previously included in the genus 
Bacillus) comprises tenths of species that are facultative anaerobic 
and endospore-forming bacteria. In particular, strains of 
Paenibacillus polymyxa thrive in the plant rizhosphere, are capable 
of fixing nitrogen, suppress some plant diseases and promote a 
healthy growth in plants, such as crops and trees. Hence, P. 
polymyxa strains are used as an effective alternative to the 
chemical control against a wide set of plant pathogenic fungi and 
bacteria. Polymyxins, including colistin and circulin, are the main 
class of peptide antibiotics produced by most strains of P. polymyxa 
although other compounds are produced as well. Other strains 




The general structure of polymyxins consists of a cyclic 
heptapeptide unit (amino acids 4-10) and a lipotripeptide that 
bifurcates from the fourth amino acid of the sequence (Figure 1). 
The lipid unit capping  the N-terminal amino acid is a linear or 
branched fatty acyl moiety, that together with amino acids in the 
6th and 7th position define the hydrophobic features of the 
molecule. The rest of amino acid residues are polar (L-threonines) 
and amino-containing basic residues (2,4-diaminobutanoic acid) 
that provide polymyxins with its polycationic nature at physiological 
pH. Polymyxins are secondary metabolites generated by non-
ribosomal peptide synthetase enzyme complexes. Hence, they 
contain non-proteinogenic amino acids as well (not present in 
regular coded proteins) such as the above mentioned 2,4-
diaminobutanoic acid, D-phenylalanine or D-Leucine. 
 
Please do not adjust margins 
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The first polymyxins discovered were reported almost 
simultaneously by three different teams in 1947: Benedict and 
Langlykke,
1
, Stansly and coworkers
2
 and Ainsworth and coworkers.
3
 
Ainsworth called the antibiotic "aerosporin" since it was obtained 
from Bacillus aerosporus which later was found to be B. polymyxa, 
essentially the same studied by Benedict and Langlykke. The 
antimicrobial "aerosporin" is now known as polymyxin A, whereas 
the so-called “polymyxin” described by Stansly corresponds to 
polymyxin D. Further investigations by Brownlee and Bushby 
managed to isolate a third type of polymyxin, which was named 
polymyxin B, and later, polymyxins C and E were found. Polymyxins 
A, B, C, D and E showed similar antibacterial activity, but an in vivo 
assay of nephrotoxicity in Wistar rats by estimating the total protein 
excreted in the urine indicated a striking increase of proteinuria for 




In parallel, Koyama described in 1950 the isolation of an antibiotic 
from a culture broth of a new strain they named Bacillus polymyxa 
var. colistinus (Aerosporus colistinus).
20
 The new compound was 
called colistin, and chemical determination proved it to be cyclic 
and share an amino acid composition qualitatively identical to that 




In 1948, Tetrault and coworkers isolated another antibiotic peptide 
that named circulin as it was produced by Bacillus circulans. It was 
found to share a similar composition to the one of polymyxins 
known so far. It was also active against Gram-negative bacteria. In 
the following years, other members of the family were discovered, 
such as polymyxin M found in the soil of Moscow by Khokhlov and 
coworkers.
21,22
 More recently, Martin and coworkers have isolated 
mattacin, a cyclic lipodecapeptide produced by Paenibacillus 





Polymyxin P, described for the first time in 1969, has been recently 
found to be the main compound produced by P. polymyxa M-1. 
Polymyxin P suppressed the growth of phytopathogenic 
Enterobacteriaceae bacteria Erwinia amylovora Ea 273, and E. 
carotovora, the causative agents of fire blight (in apples and pears) 
and soft rot, respectively. Hence, it has been proposed as an 
alternative of chemical bactericides to control these and other plant 




Other polymyxins, such as polymyxin S1 and T1 were isolated from 
P. polymyxa Rs-6 and E-12, respectively. Polymyxin T1 was found to 
be active not only against Gram-negative bacteria but also against 
Gram-positive bacteria, a characteristic shared with polymyxin 
M.
25-29
 Polymyxin F, produced by Bacillus circulans ATCC 31228, has 
also been described.
30
 Similarly, polymyxin C has also been reported 





The last members of the polymyxin family described so far were 
diasteromers of polymyxin B, named PMB1 and PMB2.
33
 They were 
produced by P. polymyxa PKB-1 and had a D-Dab amino acid in 
position 3 rather than the usual L-Dab. Their sequences were 
elucidated by high-resolution mass spectrometry, MS/MS 





Finally, it is worth mentioning a family of natural products called 
octapeptins, first reported in the mid 1970's.
22
 They are closely 
related to polymyxins as both families share a similar structure. 
They consist of a cyclic polycationic peptide sequence, containing a 
high percentage of 2,4-diaminobutanoic acid and a fatty acyl tail 
bound through an amide linkage. However, octapeptins contain 
eight amino acid residues as it may be deduced from its name,  with 
a single exocyclic amino acid stemming from the cycloheptapeptide 
moiety. A review on octapeptins has recently been published in this 




3. Antimicrobial profile  
Polymyxins are narrow-spectrum antibiotics since they are only 
active against Gram-negative bacteria including multi-drug resistant 
(MDR) strains. This includes some non-fermenting bacteria such as 
P. aeruginosa and Acinetobacter spp. and some members of the 
Enterobacteriaceae family, Escherichia spp, Klebsiella spp, 
Enterobacter spp, Citrobacter spp, Salmonella spp, Shigella spp and 
Haemophilus spp, and Pasteurella spp. However, Proteus spp, 
Burkholderia spp, Serratia spp (i. e. Serratia marcescens) and 
Moraxella spp (i. e. Moraxella catarrhalis) and genera Brucella, 
Neisseria, Chromobacterium and Providencia, have intrinsic 
resistance to polymyxins.
35
 Finally, it has been reported that 
polymyxin E was found to be active against some mycobacterial 
species, e.g. Mycobacterium xenopi, M. intracellulare, M. 
tuberculosis, M. fortuitum, M. phlei and M. smegmatis.
36,37
 




4. Commercially available polymyxins 
Since polymyxins are manufactured by fermentation procedures, 
they have a heterogeneous composition. They contain several 
structurally related components such as isomers and homologous 
compounds (Table 1). For instance, the major constituents of 
polymyxin B obtained from P. polymyxa are the related polymyxins 
B1, B2, B3 and B1-Ile, differing only in the fatty acyl moiety and the 
amino acid in position 7 (Leu or Ile). Their composition and 
antibacterial activity have been recently studied in detail. A typical 
proportion of components in polymyxin B would be ca 70-74% of 
the B1 type, 13-16 % of B2, 3-5% of B3 and around 8-9 % of Ile-
B1.
39,40
 The activity of some of these components have been 
assessed individually in strains of P. aeruginosa, A. baumannii and 
K. pneumoniae including multi-drug resistant isolates. The results of 
antimicrobial activity measured by means of their MIC (minimal 
inhibitory concentration) showed differences within the variability 
generally accepted for such a kind of assays. Apparently, the minor 
structural differences (length of the fatty acid tail and compound 
isomers)  among the components did not affect much their in vitro 
potency.
40,41
  Nevertheless, it is worth mentioning that one of the 
minor components, polymyxin B3, showed higher activity than the 
rest against P. aeruginosa, E. coli and K. pneumoniae 
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while the compound  B1-Ile was more potent against A. baumannii.  
In the same study, synergism between the different members of the 
polymyxin B mixture following checkerboard analyses was explored. 
The tests revealed that the combination of polymyxins B3 and B1-
Ile met the criteria for synergy against Enterobacteriaceae whereas 
the major components polymyxin B1 and B2 showed a low 




Regarding the pharmacokinetics of individual polymyxin B major 
components, no considerable differences were detected among 
them when tested in the rat animal model and in humans. In fact, it 
has been proposed as a reasonable approach to use the combined 
concentration values of the individual polymyxin components in 





In another study comparing polymyxin B and colistin in the rat 
model, the individual major components of polymyxin B (B1 and B2) 
and colistin (A and B) yielded similar pharmacokinetic parameters 
such as clearance, volume of distribution, elimination half-life, and 
urinary recovery. Notwithstanding that, colistin A (polymyxin E1) 
and colistin B (polymyxin E2) displayed lower protein binding in rat 
plasma compared to polymyxins B1 and B2. 
 
In relation with the accumulation of the individual products (B1, B1-
Ile, B2+B3) in kidney, a fact that correlates with nephrotoxicity (see 
section 10 below), the relative proportions of the components 
present in the renal tissue at 48 h were found to be comparable to 
the concentrations in the USP (United States Pharmacopeia) 





Commercial polymyxin B is available in the sulfate form either for 
parenteral (intravenous and intramuscular), topical (ophthalmic and 
otic instillation), and intrathecal use (in cases of MDR Gram-
negative caused meningitis). The dosage of intravenous polymyxin B 
is  generally 1.5-2.5 mg/kg/day (15.000-25.000 IU/kg/day; 1 mg of 
polymyxin B corresponds to ca 10.000 IU, International Unit), 
However, commercial formulations of polymyxin B are not always 
available in many countries of the world. Injectable polymyxin B and 
colistin formulations are available only in Brazil, Malaysia, 
Singapore and the USA while in Europe and Australia, 
colistimethate is the only parenteral formulation that can be found. 
For the treatment of eye infections caused by P. aeruginosa, 0.1-
0.25% polymyxin B solutions (10.000 IU to 25.000 IU/ml) are 
recommended. Polymyxin B in combination with a local anaesthetic 
(i. e. lidocaine, procaine) can also be found for intramuscular 
administration, in eardrops, and ointments. Combination with 




Colistin has two commercially available forms: colistin sulfate and 
sodium colistimethate (sodium colistin methanesulfonate, CMS, 
Figure 2).
47
 Both contain different proportions of colistin A 
(polymyxin E1), and colistin B (polymyxin E2), which account for 
more than 80% of colistin, together with many other minor 
components.
6
 Colistin sulfate may be administered orally for bowel 
decontamination or topically as a powder for the treatment of 
 
Figure 2: Structure of sodium colistimethate and colistin A 
(polymyxin E1). Molecular weight of colistimethate is 1749.81 
g.mol
-1
 (C58H105N16O28S5Na5) while for the free base (devoid of 
sodium methylsulfonate derivatisation) it is 1169.48 g.mol
-1
 
(C53H100N16O13). Hence, 1 mg of colistimethate corresponds to 0.67 
mg of free base colistin (or 0.81 mg of colistin sulfate, assuming 2.5 
mols of sulfate per mol of colistin) 
 
bacterial skin infections. Colistimethate is a prodrug of colistin. It is 
produced by the reaction of colistin with formaldehyde and sodium 
hydrogensulfite (see section 10 below). It is less toxic than colistin 
sulfate since it is polyanionic, but devoid of antimicrobial activity. It 
can be administered parenterally (intravenously, intramuscularly), 
intrathecally, intraventricularly or by inhalation (aerosolized, to 
treat respiratory tract infections caused by multidrug-resistant 
Gram-negative bacteria, and cystic fibrosis). Colistimethate as a 
prodrug, slowly reverts to colistin although hydrolysis is not always 
complete.
48,49
 It has been reported that only a 31.2% of CMS is 
hydrolysed in vitro to colistin in 4 hours at 37°C in human plasma.
50
  
In vivo, even smaller proportions of colistimethate are converted to 
colistin.
51
 This has been attributed to the slow hydrolysis rate of 
colistimethate to colistin combined with a fastest rate of renal 
clearance. In fact, it is estimated that only ca 25% of colistimethate 
is converted to active colistin in patients with normal renal 
function.
52
   
 
Colistimethate  intravenous dosage in adult patients with normal 
renal function are different in Europe and USA. In Europe 
colistimethate doses are in general 4-6mg/kg (50.000-75.000 IU/kg 
daily; 1 mg of colistimethate corresponds to 12.500 IU). In France 
and Austria, it reaches values of 12mg/kg (150000 IU/kg/day). In 
the USA, the recommended dose is 2.5-5 mg/kg expressed in terms 
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Examples of polymyxin drug brands approved by the FDA and 
present in the market include Pediotic®  (neomycin, polymyxin B 
sulfate and hydrocortisone suspension, USP,  for otic use), 
Polysporin®  (polymyxin B, zinc bacitracin and gramicidin; aerosol, 
topical, and ophthalmic), Neosporin® (polymyxin B, zinc bacitracin 
and neomycin triple ointment) and Polytrim® (polymyxin B sulfate 
and trimethoprim ophthalmic solution, USP). Colomycin® and 
Coly-Mycin® contain colistin methanesulfonate as the active 
principle (1-2 million units, for injection). Polymycin B sulfate 
(polymyxin B sulfate) was approved by the FDA in 2011 for the 
treatment of infections caused by resistant strains of P. aeruginosa, 




5. Mechanism of action  
Polymyxins have a narrow antimicrobial spectrum with selectivity 
for Gram-negative bacteria. This is because the first molecular 
target of these polycationic lipopeptides is the lipopolysaccharide 
(LPS), the main component of the outer membrane (OM) of Gram-
negatives.  The low permeability of the two-membrane cell 
envelope in Gram-negative bacteria is the main reason for the low 
hit rate in the discovery of new antibiotics against this bacterial 
class.
55
 The outer membrane is an asymmetric bilayer of LPS in the 
outer monolayer, and a mixture of phospholipids in the inner.
 56,57
  
LPS is composed of three domains: lipid A, central core 
oligosaccharide, and outermost O-antigen chain.
58
 Lipid A is the 
domain responsible for outer membrane thigh packing, and the 
principal target for polymyxins. It contains an N- and O-acylated 
diglucosamine bisphosphate backbone, and forms a highly packed 
structure. Although there are many variations among species, in 
polymyxin-sensitive bacteria LPS has several anionic charges, 
responsible for the strong electrostatic interactions with 
polycationic polymyxins. LPS molecules are bridged and partly 




, thus conferring a high 
rigidity and low permeability to the outer membrane.
56,59
 
The antimicrobial activity of polymyxins begins by competitive 





, thus causing a destabilization of the LPS layer and allowing 
insertion of the hydrophobic acyl chain of the antibiotic, which 
locates in the hydrophobic domain of lipid A.
60,61
 This causes an 
expansion of the LPS monolayer
15,62
 and results in disruption of the 
outer membrane permeability barrier, facilitating the entrance of 
polymyxin into the periplasmic space, a process of self-promoted 
uptake first described by Hancock.
63,64
 Binding to LPS is a required 
first step for antibacterial activity, but it is not enough. For example, 
deacylated polymyxin B nonapeptide, lacking the N-terminal acyl 
chain and Dab
1
 residue, is an extremely poor antibiotic, but is still 
capable of binding to LPS and preserving a significant OM-
permeabilizing action.
14
 This susceptibility explains the drastic 
sensitizing action of the nonapeptide, allowing other small 
molecules (such as conventional antibiotics) to cross the outer 
membrane.
65
 In addition, polymyxin resistance is related to lipid A 
modification with phosphoethanolamine and/or galactosamine, or 




The interaction of PxB and PxB nonapeptide with LPS has been 
studied in detail at the molecular level, and involves hydrophobic as 
well as electrostatic interactions. The structure of PxB bound to LPS 
has been determined by NMR spectroscopy,
67-70
 and consists in an 
envelope-like fold of the peptide ring separating the polar/charged 
residues from the hydrophobic components, conferring an 
amphiphilic character to the structure. It is postulated that the β-
turn structure is stabilized by hydrophobic interactions involving 





on the peptide ring, and the N-terminal fatty acid chain, with the 
aliphatic chains of lipid A.
65,68
 The electrostatic interactions 
between the positive side chains of Dab residues on PxB and two of 
the negative phosphate groups of the phosphorylated lipid A 
headgroups are essential for complex formation, whereas the 
hydrophobic interactions are responsible for insertion into the 
outer membrane hydrophobic core. The structure of PxB 
nonapeptide bound to LPS has been determined by tranferred 
nuclear Overhauser effect NMR and molecular dynamics,
70
 and is 
consistent with surface binding of the peptide, without insertion 
into the hydrophobic core of lipid A. This will explain the lack of 
antibiotic activity, since the nonapeptide will not reach the inner 
membrane.  
Once polymyxin has crossed the outer membrane, it must interact 
with the cytoplasmic or inner membrane in order to kill the 
bacteria.
11
 The inner membrane in Gram-negative bacteria is mostly 
composed of zwitterionic phospholipid phosphatidylethanolamine 
(PE) and anionic phosphatidylglycerol (PG) and cardiolipin (CL). All 
bacteria have at least a 15% of anionic lipids, but this can be either 
PG or CL or both.
57
 The same lipids are found in the inner layer of 
the outer membrane, although the proportions are different.
71
 The 
mechanism of bacterial killing is not related with membrane 
permeation, which takes place at concentrations well above the 
minimal inhibitory concentration.
62,72,73
 A threshold concentration 
of PxB is required on the membrane to form clusters that insert and 
form depolarizing ion-permeable pores, however dissipation of the 
pH gradient is not observed in E. coli after PxB treatment, and the 
bactericidal effect is expressed at lower concentrations and is not 
dependent on depolarization of the outer membrane.
74
 Although a 
mechanism of bacterial killing based on disruption of the physical 
integrity of the cytoplasmic membrane by pore formation or even a 
detergent effect are demonstrated for other AMPs,
75
 in the 
polymyxin family such effects only occur at high peptide/lipid ratios. 
 
A more likely mechanism of action has been described for 
polymyxin B that involves contact formation between the outer and 
inner membranes of Gram-negative bacteria,
71,76
 also seen in other 





to this model, once in the periplasmic space stoichiometric amounts 
of polymyxin will form contacts between the two enclosed 
phospholipid interfaces, and promote a fast and selective exchange 
of anionic phospholipids. The resulting changes in the membrane 
lipid composition trigger an osmotic imbalance that leads to 
bacterial stasis and cell death.
79
 Biophysical studies using model 
membranes have demonstrated that at the concentrations around 
the MIC, PxB and colistin induce the apposition of anionic vesicles 
with a composition that mimics the bacterial membrane, and the 
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formation of functional vesicle-vesicle contacts.
80
 These contacts 
support a fast and selective exchange of phospholipids exclusively 
between the outer monolayers of the vesicles in contact and 
maintaining intact the inner monolayers and the aqueous 
contents.
81
 For example, monoanionic phospholipids such as 
phosphatidylglicerol are transferred through the contacts, whereas 
zwitterionic phosphatidylcholine or dianionic phosphatidic acid are 
excluded, independently of the composition of the fatty acid chains. 
The non-antibiotic derivative polymyxin B nonapeptide is not able 
to induce vesicle-vesicle contacts.
82
  Sublethal concentrations of 
PxB in growing E. coli induce a highly selective cellular stress, with 
transcription of the osmY gene without leakage of solutes and 
protons.
 71,77,79
 Since osmY expression is also induced by 
hyperosmotic stress, encoding a periplasmic protein that protects 
from cell membrane damage,
83
 the interpretation is that PxB forms 
functional contacts in the periplasmic space between the anionic 
phospholipid-containing outer surface of the cytoplasmic 
membrane and the inner surface of the outer membrane.
84
  The 
consequent loss of phospholipid compositional specificity caused by 
the PxB-mediated exchange can be the origin of the osmotic 
imbalance that leads to bacteriostasis and cell death.
14
 An analysis 
of the transcriptome of A. baumannii exposed to colistin shows that 
this antibiotic alters the expression of a very large number of genes, 
many of them involved in the synthesis and transport of membrane 
components. This is consistent with the inner membrane-outer 
membrane lipid exchange mechanism of action with alteration of 




The structure of polymyxin in the IM-OM contacts has been 
characterized in lipid vesicles by fluorescence resonance energy 
transfer, using labelled derivatives of a synthetic PxB analog, sp-B.
86
 
Intermolecular FRET is consistent with self-association of the 
peptide, possibly forming dimers, when bound to anionic vesicles at 
concentrations that are relevant for formation of vesicle-vesicle 
contacts and lipid exchange. Atomic force microscopy of polymyxin 
bound to monolayers of E. coli lipid extract shows structures that 
are consistent with the formation of aggregates of several particles 
at the concentrations that induce contact formation.
82
   
 
A series of polymyxin analogs obtained by solid phase synthesis and 
including a disulfide bond gave additional information on the 
mechanism of action. For example, conservative analogs 
maintaining the main structural characteristics of polymyxin, 
namely 5 positive charged residues, a cyclic heptapeptide, a lineal 
tripeptide and the N-terminal acyl chain, are also active against 
Gram-negative bacteria and induce vesicle-vesicle contacts and a 
selective lipid exchange similar to polymyxin.
87,88
 However, 
substitution of Dab residues for Arg results in more lytic 
lipopeptides, with a different spectrum of activity that includes 
Gram-positive and Gram-negative bacteria.
89,90
 Flow citometry of E. 
coli treated with one of the Arg-containig polymyxin analogs shows 
that depolarization and permeabilization take place roughly at the 
same time, and are consistent with a membrane-based mechanism 
of action.
89,91
 It has also been shown that polymyxin B and colistin 
are able to inhibit the vital respiratory enzyme type II NADH-
quinone oxidoreductase (NDH-2) in the inner membrane of Gram-






Figure 3: Representation of the putative mechanism of action of polymyxin 




 and binding 
to lipid A; (2) Self-promoted uptake to the periplasmic space and formation 
of OM-IM contacts and lipid exchange; (3) Inhibition of respiratory enzyme 
type II NADH-quinone oxidoreductase; (4) Entry into the cytoplasm and 
access intracellular targets. *Polymyxin B nonapeptide activity is limited to 
step (1). 
 
Interestingly, polymyxin B nonapeptide has no inhibitory activity, in 
agreement with its reported inability to cross the cell membrane. 
NADH-2 inhibition has also been identified in other compounds 
including phenothiazines, quinolinyl pyrimidines and quinolones, 
but in all cases the mode of action remain unclear and in the case 
of polymyxins is considered a secondary mechanism of action.
93 
Polymyxin B and E can inhibit alternative membrane bound 
respiratory enzymes nicotinamide adenine dinucleotide 





Some reports suggest that entry into the cytoplasm of the bacterial 
cell is not necessary for activity. For example, polymyxin B 
covalently attached to agarose beads has a good antimicrobial 
activity on E. coli and P. aeruginosa.
94
 It is proposed that 
perturbation of outer membrane structure by polymyxin-agarose 
indirectly affected the selective permeability of the inner 
membrane and inhibited respiration. However, the chemistry 
followed in this study did not provide selectivity to the anchoring 
point on the peptide, given that it includes multiple free amines, 
any of which could have reacted with the spacer arm bound to the 
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battacin, a close analog of polymyxin that retains its activity when 
covalently linked to a derivatized solid surface, being a promising 
agent as antibacterial surface coatings to prevent bacterial 
colonization and biofilm formation.
95
 The lipopeptide-coated 
surfaces caused significant damage to the cellular envelope of P. 
aeruginosa and E. coli upon contact and prevented surface biofilm 
colonization.  
 
It should be stressed that the mechanism of action of polymyxins on 
Gram-negative bacteria based on OM and IM interactions is well 
documented. However, other mechanisms involving intracellular 
targets can also play a role.
15,96
 Recently, entry of polymyxin into 
the cytoplasm of Gram-negative bacterial cells has been 
demonstrated by time-lapse laser scanning confocal microscopy 
using a dansylated polymyxin B that maintains the pharmacological 
properties of the natural antibiotic.
97
  In their work, the authors 
show that labelled polymyxin initially accumulated in the OM of K. 
pneumoniae, then it gradually penetrated the OM and accessed the 
IM, and only at high concentrations (5 x MIC) it became 
homogeneously distributed in the cytoplasm. The possibility of 
intracellular targets for polymyxins is not clear, but there are some 
studies that point in that direction.  For example, the generation of 
hydroxyl radical production by the Fenton reaction leading to the 
formation of hydroxyl radicals through the reduction of hydrogen 
peroxide by ferrous ion (Fe
2+
) has been observed in several Gram-
negative species, including A. baumanii and E. coli,
76,98
 and K. 
pneumoniae.
99
 The production of reactive oxygen species (ROS) is 
concurrent with the rapid killing of these bacteria by both 
polymyxin B and colistin, probably by oxidative damage in the 
bacterial DNA, proteins and lipid.
100
 In support of this intracellular 
mechanism of action, a study by Pournaras et al.
101
  shows that in a 
colistin-resistant isolate of A. baumanii there is a significant 
decrease in the expression of enzymes involved in oxidative stress 
response. An increase in expression of genes encoding superoxide 
dismutase enzymes after colistin treatment in A. baumanii also 




6. Resistance to polymyxins  
The therapeutic rescue of polymyxins for their use in nosocomial 
infections has been followed by an emergence of acquired 
resistance among the most clinically relevant Gram-negative 
bacteria. Resistance to polymyxin is a complex subject that would 
require of another thorough review by itself. Hence, only a brief 
mention will be made here. Several recent reviews summarizing the 
mechanisms of resistance to polymyxins are also available.
 53,102-105
 
As seen before, the first molecular target of polymyxins in the 
bacterial surface is the LPS of the outer membrane. Since 
electrostatic interactions are established with anionic phosphate 
groups in lipid A, modification of those with positively charged 
groups such as phosphoetanolamine or 4-amino-4-deoxy-
L-arabinose provides a mechanism of protection from the 
interaction with polycationic polymyxin and thus, of resistance.
106
 
Changes in lipid A may include deacylation, hydroxylation and 
palmitoylation. Other mechanisms of resistance include the 
utilization of efflux pumps and capsule formation. Resistance is 
mainly adaptive (reversible) and regulated by two-component 
systems (e. g.  PhoP/PhoQ and PmrA/PmrB) and can be triggered by 
environmental stimuli (low Mg
2+
 levels, sublethal concentrations of 
AMPs, for instance). Recently, resistance to colistin due to plasmid-
mediated mcr-1 gene has also been described. MCR-1 is a 
phosphoethanolamine transferase enzyme (it adds 
phosphoethanolamine to lipid A). Resistance to polymyxins is 
certainly an added challenge to the development of new antibiotics 
against pan-drug resistant Gram-negative bacteria.
107
 
7. Combination with other antibiotics 
The main interest of polymyxin combinations with other antibiotics 
lies in the treatment of infections caused by resistant and 
multidrug-resistant bacteria whose proliferation is becoming a 
serious social and economic problem worldwide and account for 
growing global morbidity and mortality. Multidrug-resistant 
pathogens are considered those that are resistant to three or more 
antibiotic classes. The worst are the extensively drug-resistant 
(XDR) ones, particularly those Gram-negative pathogens that are 
non-susceptible to all but one or two antibiotic classes.108 In this 
situation, when even carbapenems, a major last-line class of 
antibiotics to treat bacterial infections, are not useful polymyxins 
have been rescued and become last-resort agents against XDR P. 
aeruginosa, K. pneumoniae and A. baumannii.  
 
The emergence of polymyxin-resistant strains and polymyxin 
heteroresistance (heterogeneity of response to antibiotics from 
bacterial cells within the same population) is questioning the utility 
of polymyxin monotherapies. Increasing the dose to maximize 
efficacy of the treatment is not viable since polymyxins are 
nephrotoxic and exhibit a narrow therapeutic index. An alternative 
option would be the administration of polymyxins in combination 
with other antibiotic agents or non-antibiotic compounds.109  The 
mechanism of action of polymyxins, that affects the integrity and 
enhance permeability of the outer membrane of Gram-negative 
bacteria, may help increase activity and accumulation110 within 
bacterial cell of other antibiotic classes. 
 
Several studies have explored the synergistic activity of polymyxins 
with other antimicrobial agents against Gram-negative bacteria, 
particularly P. aeruginosa, K. pneumoniae and A. baumannii. 
Synergy may be assessed in vitro by three methods:  time-kill 
studies, Etest and microdilution. The major interest of combinations 
is to show synergistic activity against resistant bacterial strains to at 
least one of the antibiotics, chiefly the one showing the highest 
MIC. One of the antibiotic classes most commonly used in 
combination with polymyxins is the carbapenem family. In a 
systematic review and meta-analysis, combination therapy 
following the time-kill method showed synergy rates of 44% (30 to 
59%) for K. pneumoniae, 50% (30 to 69%) for P. aeruginosa and 77% 
(64 to 87%) for A. baumannii. Of the carbapenems studied, 
doripenem showed high synergy rates for all three bacteria. 
Meropenem was more synergistic for A. baumannii and imipenem 
for P. aeruginosa. Etest and checkerboard assays generally yielded 
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 have been described to confer 
additive bactericidal activity against several P. aeruginosa strains in 
vitro. Regarding K. pneumoniae, efforts have been mostly devoted 
to K. pneumoniae carbapenemase (KPC) and metallo-β-lactamase 
(MBL) producing strains.
121



















The combination therapy of polymixin with rifampicin is one of the 
most tested options for the treatment of MDR and XDR Gram-
negative bacterial infections, and A. baumannii is no 
exception.
130-134
 A lot of attention has also received the synergistic 
studies of polymyxins with glycopeptides (teicoplanin, vancomycin, 
telavancin).
124,135-141
 Partial synergy has been observed with 
azithromycin.
142





 and daptomycin, an 
anionic lipopeptide, has also been shown.
145
 Finally, the 
combination of lantibiotic nisin (normally used as a food 
preservative) with either colistin or polymyxin B yielded a 
pronounced synergistic effect in E. coli, K. pneumoniae, P. putida 
and P. aeruginosa.
146
 However, no additive effect was found with 
nisin in binary combination with penicillin, erythromycin or 
chloramphenicol. 
 
In summary, numerous studies have identified various polymyxin 
combinations presenting synergistic activity against sensitive and 
multi-drug resistant P. aeruginosa, K. pneumoniae and A. 
baumannii. Apparently, synergy was more evident in polymyxin-
resistant strains, what augurs well for the combination therapy in 
front of polymyxin monotherapy. In addition, regrowth and 
emergence of resistance is consistently seen in polymyxin 
monotherapy. Given this situation, polymyxin combination therapy 
could reduce the possibility for selection of resistant 
subpopulations or the development of new resistance. Although 
most in vitro data endorse this view, clinical investigations of 
polymyxin combination therapy are in its infancy. So far, clinical 
data is apparently inconclusive in showing evident superiority of the 
cotherapy due to the small sample size studies, among other 
reasons.
53,147-149
 To overcome this issue, well-designed clinical tests 
are urgently needed to give a clear answer. In this regard, two large 
clinical trials comparing colistin monotherapy and colistin combined 




8. Synergy with antifungals 
Polymyxins are known to have a poor fungicidal activity (MIC ≥ 8 
mg/L). However, the synergistic antifungal properties of polymyxin 
B were studied as early as 1972. Polymyxin was found to potentiate 
the activity of tetracycline in Candida albicans and Saccharomyces 
cerevisiae, even at low concentrations. Polymyxin B seemed to 
increase the permeability of the yeast cell membrane to 
tetracycline, which then inhibited protein synthesis and led to cell 
death.
151
  More recently, it has been demonstrated that the 
polymyxin B combination with fluconazole or itraconazole was 
active at low concentrations against Aspergillus fumigatus, Rhizopus 
oryzae, Candida albicans and non-albicans Candida species. The 
combination at clinically relevant low concentrations was 
particularly potent against Cryptococcus neoformans, including 
strains resistant to fluconazole.
152
 Polymyxin B has also been 
demonstrated to reduce the tissue fungal burden both in 
intravenous and inhalation models of murine cryptococcosis at a 




Synergistic antifungal activity against C. albicans has also been 
reported when polymyxin B was combined with amphotericin B, 
ketoconazole and miconazole.
153,154
 Similarly, colistin has also been 
found to act synergistically with amphotericin B against R. oryzae.
155
 
Colistin, both as a single agent or in combination with voriconazole, 
caspofungin and amphotericin B, has also shown in vitro antifungal 
activity against filamentous ascomycetes occurring in cystic fibrosis 





In a recent study to assess the in vitro susceptibility of 25 clinical 
isolates of Fusarium to antifungal agents (amphotericin B, 
caspofungin, itraconazole and voriconazole) and antimicrobials 
(pentamidine, polymyxin B, tigecycline and tobramycin), the highest 
rates of synergism were observed when amphotericin B or 
voriconazole were combined with tobramycin (80 % and 76 %, 





Finally, caspofungin and echinocandin antifungals in combination 
with colistin have also been found to act synergistically against 
fluconazole-resistant and susceptible C. albicans and C. glabrata 
isolates. However, authors also state that the correlation with in 
vivo benefits may not be straightforward.
159-161
  
9. Antibiofilm activity  
A biofilm is an organized microbial ecosystem that consist of one or 
more microbial species imbedded in a self-produced matrix of 
extracellular polymeric substances composed by proteins, 
polysaccharides and DNA. Biofilms can develop on human body 
tissues and surfaces of medical devices. Antibiotic treatments 
against biofilms usually require of high doses administered for long 
periods of time. Since current available antibiotics have been 
developed to target planktonic bacteria, they often fail to fight 




Polymyxins have been proven to be active against biofilms, both as 
a single agent or in combination with other antibiotics, particularly 
against A. baumannii and P. aeruginosa.
163,164
 However, neither 
colistin nor polymyxin B were found capable of preventing 
(p)ppGpp accumulation (alarmones guanosine 5’-diphosphate 
3’-diphosphate, ppGpp, and guanosine 5’-triphosphate 
3’-diphosphate, pppGpp) signaling nucleotides that regulate the 
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Polymyxin was found to show an antibiofilm synergistic interaction 
with cyclic antimicrobial peptide gramicidin S toward 17 multidrug-
resistant P. aeruginosa and biofilms of P. aeruginosa strain PAO1. 
The concentration of polymyxin B required to inhibit biofilm 
formation by P. aeruginosa PAO1 was 8 μg/ml. Treatment in 
combination with gramicidin S required only  2 μg/ml (gramicidin S  
concentration got reduced from 32 μg/ml to 4 μg/ml ). The FIC 
(fractional inhibitory concentration) calculated from this decrease 
was 0.375, which indicated a synergistic effect of this treatment.
118
 
Inhibition of biofilm formation by P. aeruginosa (PA-01 strain) has 
also been found between nisin lantibiotic and either colistin or 
polymyxin B. As a control, none of these antimicrobials inhibited 




Colistin and tobramycin, both alone or in combination exhibited 
bactericidal activity prior to biofilm attachment to endotracheal 
tubes, however no activity was observed once biofilm formed on 
such polyvinylchloride tubes.
166
 Polymyxin B proved to be 100% 
effective in vitro against a highly prevalent clone of multi-drug 
resistant A. baumannii, with a 92.9% of strains being biofilm 
producers (associated patient lethality of 28.2% in a Mexican 
Tertiary Care Hospital). However, no direct proof of polymyxin 




Recently, colistin entrapped in nanoparticles of different materials 
[poly (lactide-co-glycolide, chitosan, poly(vinyl alcohol] have been 
proven to eradicate pre-formed P. aeruginosa biofilms. 
Nanoparticles of colistin/poly(vinyl alcohol) and colistin/chitosan 
could penetrate inside the biofilms, release colistin in situ, thus 
increasing the effectiveness of the treatments.
168,169
 A synergistic or 
additive effect between colistin and levofloxacin has been reported 
in vitro and in Galleria mellonella model against colsitin-susceptible 
A. baumannii strains, although not against colistin-resistant ones.
170
 
10. Toxicity  
Toxicity of polymyxins has been reported since the beginning of its 
use. Toxicity is dose dependent and reversible once the treatment is 
discontinued. However, the exact molecular mechanism of toxicity 
is not well-understood.  
 
In 1947, Stansly and coworkers already described the 
sulfomethylation of polymyxin to reduce acute toxicity, according to 
previous reports describing the significance of transforming a 
cationic drug into an anionic one:  
 




 + H2O 
 
They also observed that this sulfomethylated form of polymyxin 





The main adverse side effects of polymyxins are nephro- and 
neurotoxicity.
171,172
 The rate of colistin-associated neurological 
toxicity is approximately 7%. The major manifestation of neurotoxic 
side effects after parenteral colistimethate administration is 
paresthesia (“pin and needles sensation”).  Neuromuscular 
blockade can also occur during polymyxin therapy although no 
episodes have been reported in the literature in the last years. 
Ataxia, vertigo, confusion, dizziness, weakness, visual, speech 
disturbances, hallucinations and seizures are also possible during 
polymyxin therapy.  
The major toxicological problem of polymyxins is nephrotoxicity. 
Both polymyxin B and colistin/colistimethate are known to produce 
adverse side effects in kidney.
171,172
  Nephrotoxicity rates typically 
range between 10% and 60%. In the largest clinical study so far 
performed (258 patients) the rate of nephrotoxicity was found to 
be 10%.
173
 In a series of recent studies carried out in cohorts of 71 
and 66 patients, acute kidney injury (AKI) rates associated to 
colistimethate administration were found to be 45-56% according 
to the Risk, Injury, Failure, Loss and End-stage (RIFLE) kidney disease 
criteria.
174,175
 In a study performed in Korea, AKI incidence was 
found to reach  54.6 % in a cohort of 119 patients.
176
 In another 
study involving 92 patients comparing a high-dose of colistimethate 
treatment (9 MIU, million IU, followed by a maintenance dose of 
4.5 MIU/12 h) versus the standard dose (6 MIU/day ), a higher cure 
rate in the high-dose group was found (63 vs. 41.3%, p = 0.04) with 
no higher risk of nephrotoxicity (32.2 versus 26%).
177
 In a smaller 
study involving 30 patients in Orlando (Florida, US), nephrotoxicity 
occurred in 3 out of 10 (33%) of patients. An interesting point of 
this study was that excessive colistimethate dosing was frequent 
(47%), often due to the higher body weight in obese patients (71%), 
and was associated with higher rates of nephrotoxicity (80% versus 
30%). Overall, a close monitoring of the renal function in patients is 
mandatory to identify the optimal colistimethate dose from both 
efficacy and toxicity perspectives.
178
 The use of homogeneous 
criteria, such as the RIFLE one, when carrying out nephrotoxicity 
studies was also found to be necessary for the evaluation of acute 
kidney injury and allow for comparison of nephrotoxicity among 
reports. 
 
The use of potentially nephroprotective agents has been advocated 
to ameliorate adverse side effects of polymyxins (ascorbic acid, 
vitamin E, melatonin, lycopene, N-acetylcysteine). In rodent  in vivo 
models, some positive results showed that coadministration of 
antioxidants can protect against colistin-induced nephrotoxicity.
179
 
In the clinic, administration of intravenous ascorbic acid has been 
studied as a potentially useful component to prevent nephrotoxicity 
because of its antioxidant properties. However, evidence of a 





Since both polymyxins and colistimethate are nephrotoxic, a 
question rises regarding the relative toxicity of the free base in 
comparison with the methansulfonated derivative. Again, results 
are not conclusive. In a report by Oliveira in Brazil dealing with the 
treatment of infections (41 patients) caused by carbapenem-
resistant Acinetobacter spp,  both polymyxins gave equivalent 
results with regard to  efficacy and toxicity.
177
 In a systematic 
review and meta-analysis, unadjusted nephrotoxicity was more 
common in patients treated with colistin than with polymyin B, but 
according to the RIFLE criteria, there was no difference regarding 
risk, injury or failure between colistin and polymyxin B.
183
 Two other 
studies though, reported that nephrotoxicity rates were lower with 
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polymyxin B than colistimethate.
171,184,185
 Also, polymyxin B seems 
to have some advantage over colistimethate regarding rapid target 




10.1. Mechanism of nephrotoxicity  
The mechanism of polymyxin-induced nephrotoxicity is not clear 
and numerous efforts are carried out to uncover it.
187,188
 The 
structure-activity data on polymyxin analogs  seem to indicate that 
toxicity is related to the amphipathic nature of the molecule, due to 
the presence of hydrophobic residues (fatty acid, amino acids 6 and 
7) and particularly due to the presence of charged Dab side chains 
at physiological pH. Polymyxins accumulate within proximal tubular 
epithelial cells (PTEC) of the kidney via endocytosis at the 
multiligand receptor megalin. Megalin is highly expressed on the 
luminal surface of renal proximal tubules.  It is a negatively charged 
protein involved in the binding and endocytosis of polybasic 
molecules such as aprotinin, cytochrome c or aminoglycosides.
189,190
 
The mechanism of nephrotoxicity of polymyxins has been proposed 




Polymyxin-induced nephrotoxicity has been associated with acute 
tubular necrosis in kidneys and rise of creatinine levels in blood. 
Serum creatinine increments after parenteral administration of 
colistimethate are dose- and duration-dependent as proven in rats 
and humans. Phamacokinetic data indicate that polymyxins are 
extensively reabsorbed by active transport processes in the renal 
tubules after filtration at the glomerulus (from tubular urine back 
into blood).
193
 This major tubular reabsorption may induce an 
accumulation of the drug in the tubular cells and this could be, at 
least in part, a potential cause for nephrotoxicity. Accumulation of 
polymyxin induces apoptosis in kidney tubular cells
194
 and may be 
the result of mitochondrial damage and/or release of reactive 
oxygen species.
187
 The urinary recovery of polymyxin B and colistin 
is less than 1%, as proven in humans and rats, respectively. Thus, it 
is evident that nonrenal elimination is the predominant clearance 
pathway for both polymyxins. However, the urinary recovery of 
sodium colistimethate can be higher than 60% (as seen in assays in 
rats, dogs and humans). The explanation may come from the 
different ionic nature of both polymyxins (polycations) and 
colistimethate (a polyanion). Urinary concentrations of colistin after 
administration of colistimethate can be relatively high as a result of 
hydrolysis within the urinary tract from colistimethate that is 
extensively renally excreted (and not reabsorbed). Partially 
sulphomethylated derivatives of colistin are also excreted before 




Recently, a detailed study by Mass Spectrometry Imaging (MSI) 
helped to reveal the distribution of polymyxin B1, colistin, and the 
less nephrotoxic truncated derivative, polymyxin B nonapeptide 
within rat kidney.
198
 The bioanalysis showed that polymyxin B1 and 
colistin preferentially accumulated in the renal cortical region while 
polymyxin B nonapeptide, a less nephrotoxic compound, was more  
uniformily distributed throughout the kidney. Ratios of relative 






































Hydrolysis, M1, m/z = 963.5740
Minor metabolization: demethylated, oxydized polymixin
metabolites M6, M7, M9, and M10 m/z = 1203,7213
Hydrolysis, M8, m/z = 460.3135
 
Figure  4: Polymyxin B1 metabolites found in renal cortex in 
addition to polymyxin B1 itself. Metabolites were identified by 
LC/MS/MS (Liquid Chromatography, Mass Spectrometry) according 
to Nilsson and coworkers (M5, unknown structure). Arrows indicate 




for colistin and 25.4  to 1 for polymyxin B.  For polymyxin 
nonapeptide, the ratio was 2.9 to 1. These results correlate with 
recent immunohistochemical and correlative microscopy studies, 
which also demonstrated that polymyxins accumulate within renal 
tubular cells of the renal cortex.
199-202
 In addition, metabolites that 
accumulate with a similar distribution as the parent polimixins have 
also been identified by high resolution MS (Figure 4). 
 
Both tissue homogenates and urine samples were analyzed. Ten 
polymyxin metabolites were identified within the tissue 
homogenates, six of which were also found in the urine sample. No 
quantification of the relative abundances of the different 
metabolites was provided, though. Nevertheless, it is interesting to 
see that both non-metabolized polymyxin and colistin accumulate 
in renal cortex and their image intensity increases during the seven 
days of the experiment. Some metabolites imply minor 
modification (oxidation, demethylation) of the parent polymyxin, 
with small reductions of molecular weight. Other metabolites 
comprise the sequential hydrolysis of the linear lipotripeptide 
moiety without affecting the cyclic heptapeptide structure. 
Regarding colistin metabolization, similar byproducts were found. 
However, one of the metabolites detected involved the partial 
hydrolysis of cyclic structure in this case (colistin metabolite M5, 
not shown).
198
 Altogether, this study suggests that in spite of the 
fact that the majority of kidney’s drug metabolizing and 
detoxification enzymes are located in the proximal tubule,
203
 a 
significant proportion of polymyxin molecules remain non-
metabolized in renal cortex, what seems to indicate that polymyxins 
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are apparently quite stable molecules. In fact, polymyxins 
accumulate and are reabsorbed in proximal tubules, as we have 
seen before, and are mainly eliminated by non-renal clearance 
mechanisms. 
 
10.2. Biomarkers of nephrotoxicity 
Monitoring of drug-induced kidney injuries is an important issue 
during drug development. Hence, validation of kidney injury 
biomarkers is necessary for the clinical application and regulatory 
issues. In acute kidney injury according to the RIFLE criteria, the 
determination of plasma and serum creatinine levels remains as a 
standard of diagnosis. Creatinine is a useful biomarker of kidney 
damage in patients suffering of stable chronic renal diseases, but it 
is not convenient in the case of acute kidney disease. More than 
half of kidney function is lost before AKI is detected by an increase 
of serum creatinine levels as they are detected 24-48 hours 
following the initial kidney insult. Colistimethate treatments are 
often discontinued when minor increments in creatinine levels are 
detected because of the risk of negative outcomes, even if patients 
are responding to the antibiotic therapy. Hence, there is a need of 
novel kidney injury urinary biomarkers that can detect AKI much 
earlier in order to avoid such decision time lag. Several biomarkers 
are a subject of study to allow for an early and site-specific 
prediction of AKI. These indicators can detect initial kidney injury in 
4-6 hours. Biomarkers for tubular damage include Kidney Injury 
Molecule-1 (KIM-1), α–Glutathione S-Transferase (α–GST), 





KIM-1 is a type I trans-membrane structural glycoprotein present on 
epithelial cells of the renal proximal tubule. KIM-1 is undetectable 
in healthy tissue but highly upregulated on the apical surface of 
proximal tubule epithelial cells after renal injury, i. e.  in response to 
toxic and ischemic injury. The ectodomain shedding of KIM-1 into 
urine makes it an early and specific biomarker for AKI. 
 
α–GST and π–GST are small cytosolic isoenzymes and members of 
the GST superfamily. They are primarily involved in cellular 
detoxification metabolic reactions since they catalyze the 
conjugation of the reduced form of glutathione (L-γ-glutamyl-L-
cysteinyl-glycine) to xenobiotic substrates. They can form up to 2% 
of the total cytosolic soluble protein content in the cytoplasm. 
α-GST and π-GST are immediately released into the urine upon lysis 
of epithelial cells of the proximal and distal tubule, respectively, 
converting them in a rapid and sensitive biomarker of AKI. 
Simultaneous detection of both GST proteins permits discrimination 
between proximal and distal tubular damage. 
 
NGAL is small extracellular glycoprotein that is characterized by the 
ability to bind small hydrophobic molecules. NGAL is rapidly 
upregulated and thus, an early biomarker for the detection of AKI 
onset in various clinical settings including cardiothoracic surgery, 
intensive care-unit, and nephropathy. 
 
In a study carried out in rats, KIM-1 and α-GST proved to be the 
most sensitive biomarkers to polymyxin-induced AKI, outperforming 
current nephrotoxicity standards of care (creatinine and blood urea 
nitrogen) proving that they are not suitable for detecting 
nephrotoxicity of polymyxin in this in vivo model.
197
 NGAL and 
π-GST also proved to be useful indicators according to same study. 
In another in vivo study performed simultaneously in rat, dog and 
monkey, similar results were obtained for the rat model, with NGAL 
and KIM-1 capable of detecting AKI (GST biomarkers were not 
tested). However, in the dog and monkey models, both standard 
(creatinine and blood urea nitrogen) and more recent biomarkers 
(NGAL and KIM-1) showed a rapid onset of response.
204
 In this case, 
though, the added value of urinary NGAL and urinary KIM-1 
biomarkers was their selectivity in the localization of the injury 
within the kidney (proximal and/or distal tubules versus the 




11. Design and development of new polymyxins 
The growing incidence of bacterial resistance in hospitals and 
healthcare settings, the dry pipeline of new antibiotics, and the fact 
that polymyxin B and colistin have become last line antibiotics to 
treat highly drug resistant infections in spite of their toxicity 
liabilities has led to several worldwide research initiatives in recent 
years to design and develop new polymyxin analogs. The goals are 
to improve activity, reduce adverse side effects, mostly 
nephrotoxicity, and understand the relationship of activity and 
toxicity with the chemical structure of polymyxins. 
 
First efforts aiming at these objectives started in the 1970s. 
However, the difficulty in access to reliable peptide synthesis 
schemes for the preparation of cyclic peptide analogs and the 
limited knowledge of polymyxin pharmacology reduced the 
structural and chemical space of explored analogs.
14,15,206-210
 Thus, 
compounds were generated by acylation or alkylation of Dab 
residues, or substitution of the N-terminal fatty acid tail sometimes 
following semisynthetic approaches from truncated versions of 
polymyxin such as the nonapeptide (PBNP). The view that emerges 
from this initial background is that amphipathicity in polymyxins is 
crucial for activity, which includes the charged Dab residues on the 
one hand and the fatty acid tail and the conserved hydrophobic 
residues in position 6 and 7 on the other.  
 
Another trend that can be observed relates to the fact that in 
general, activity in polymyxins runs parallel to toxicity, i. e. more 
active compounds tend to be more toxic to mammalian cells. 
Hence, new approaches should be sought to break this 
activity/toxicity correlation in polymyxins. In the last decade or so, 
several academic and private teams worldwide got involved in the 
design and development of novel polymyxin analogs to overcome 
the drawbacks posed by the natural compounds, that is to say, 
improve safety and efficacy.    
 
11.1  Synthetic preparation of polymyxin analogs 
Preparation of novel polymyxin analogs is performed following two 
main approaches: semisynthesis and total chemical synthesis. The 
first strategy, semisynthesis, starts from the natural polymyxin 
product, usually obtained by fermentation procedures.
211
 Although 
this is a readily  accessible and affordable approach, it is  curtailed 
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by the few possibilities of modifying the cyclic heptapeptide core 
and normally analogs are reduced to truncation or substitutions in 
the linear lipotripeptide moiety by enzymatic treatment. Enzymatic 
hydrolysis of the linear segment of polymyxin gives access to 
truncated analogs of polymyxin, such as the deacylated 
decapeptide by means of a polymyxin acylase treatment or to the 
well-known PBNP by treatment with papain or plant proteinase 
ficin.
202-203
 Treatment with bromelain enzyme yields polymyxin 
octapeptide (polymyxin 3-10) while hydrolysis with Nagarse 
furnishes the heptapeptide (polymyxin 4-10, heptacycle devoid of 
the N-teminal lipotripeptide).
210-211
 Further elaboration of the 
polymyxin fragments is possible by means of several selective 
protection schemes (Boc, tert-butoxycarbonyl, Fmoc, 
9-fluorenylmethoxycarbonyl) and strategies as discussed below for 
each particular case.  
 
Total chemical synthesis of polymyxins generally involves the solid-
phase methodology using different polymeric supports and 
protecting groups such as Fmoc, Boc, tBu (tert-butyl), Dde (1-(4,4-
dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl), Z (benzyloxycarbonyl) 
or Bzl (benzyl). Below, efforts by private companies and universities 
devoted to the design and development of polymixins are 
summarized. 
 
11.2 CB-182,804 analog 
This was the first synthetic polymyxin B derivative that entered a 
clinical trial. Originally developed by BioSource Pharm and licensed 
to Cubist Pharmaceuticals (now part of Merck), it had its N-terminal 
fatty acyl moiety substituted by an aromatic urea, a 2-chloro-
phenylaminocarbonyl unit (Figure 5). 
 
The analog CB-182,804 was prepared by semisynthesis from natural 
polymixin obtained by fermentation. Side chain Dab amino groups 
were protected with the Sulfmoc group (HSO3-Fmoc) by reaction 
with 9-(2-sulfo)fluorenylmethoxycarbonyl-N-hydroxysuccinimide. 
The resulting penta-Sulfmoc protected polymyxin was treated with 
a deacylase enzyme (from Actinoplanes ulahensis NRRL 12052) to 
remove the fatty acid tail and the resulting N-terminal free amino 
group was reacted with 2-chlorophenylisocyanate to yield the 
o-chlorophenyl urea. Finally, the Sulfmoc protecting groups were 





In vitro activity of CB-182,804 showed MIC90 (minimal 
concentration to inhibit growth of 90% of bacteria strains) values 
for E. coli, K. pneumoniae and P. aeruginosa around 2-4 μg.mL
-1
, 
similar or slightly higher (less potent) than polymyxin 
B/colistin.
212,213 
 It was also demonstrated to be substantially less 
toxic in vitro since an EC50 of more than 1000 μg.mL
-1
 was obtained 
in rat kidney proximal tubule cell cultures whereas  EC50 was  318 
μg.mL
-1 
for polymyxin B.  
 
CB-182,804 was tested in eight rodent infection models for efficacy 
against five Gram-negative pathogens. The efficacy of CB-182,804, 
for instance, compared favorably to that of polymyxin B, colistin, 
ciprofloxacin, or imipenem-cilastatin in an in vivo model of P. 
aeruginosa lung infection in neutropenic mice. 
 
Figure 5: Chemical structure of analog CB-182,804  
 
 
Similarly, in an A. baumannii thigh infection model in neutropenic 
mice, it also compared favourably to polymyxin B, colistin or 
imipenem-cilastatin. Pharmacokinetic features showed differences 
with respect to polymyxin B, particularly, decreased serum protein 
binding, and increased plasma clearance and volume of distribution.  
 
Finally, CB-182,804 was tested in cynomolgus monkeys for renal 
toxicity in a seven-day study. CB-182,804 showed lower 
nephrotoxicity than polymyxin B. Histopathological changes were 





There was a mild associated increase in blood urea nitrogen and 
serum creatinine at higher dose with an increase in severity of 
histological kidney changes (9.9 mg/Kg/day). However, these kidney  
findings were markedly less than the ones found for polymyxin B 
when administered at equivalent antimicrobial doses. CB-182,804 
progressed into a phase I clinical trial (safety and pharmacokinetics 
in healthy humans) in February 2009 but in September 2010, it was 
discontinued. Results have apparently not been published. 
 
 
11.3 Pfizer 5x analog 
A series of biaryl and heterobiaryl N-terminal substituted 
derivatives of polymyxin have been described by Magee and 
coworkers in Pfizer.
214
 Position 3 that usually contains a Dab amino 
acid in natural polymyxins was substituted by Dap (L-1,3-
diaminopropanoic acid) in the analogs (Figure 6). This substitution 
conferred a higher antimicrobial activity and reduced cytotoxicity in 
human PTEC cells. Compounds were prepared by solid phase 
chemical synthesis on a 2-chlorotrityl chloride resin following a 
Fmoc/tBu/Z/Dde scheme of protection and macrocyclization in 
solution at high dilution conditions (0.002M). The heterobiaryl 
moiety was introduced by acylation reaction of 6-oxo-1-phenyl-1,6-
dihydropyridine-3-carboxylic acid. Antimicrobial potency of 5x was 
similar to the one of polymyxin B, as judged by MIC50 and MIC90 
(equal or half the value) against susceptible and resistant strains of 
P. aeruginosa, A. baumannii, E. coli and K. pneumoniae.  
 
Page 16 of 49Natural Product Reports
Journal Name  ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 13  
Please do not adjust margins 
Please do not adjust margins 
 
Figure 6: Chemical structure of Pfixer 5x analog  
 
 
Compound 5x showed improved cytotoxicity in human PTEC cell 
line (TC50 >100 μM) in comparison with polymyxin B (TC50 >22 μM). 
A extensive comparative in vivo safety study in rat and dog models 
was performed. In a seven-day exploratory toxicological study, 5x 
showed no incidence of necrotic kidney lesions at 4 mg/Kg/day 
dose while polymyxin B yielded necrotic kidney lesions in every 
animal although graded to be minimal. At twofold dose (8 
mg/Kg/day), 5x produced no kidney lesions whereas polymyxin B 
was not even tolerated. However, the dog model proved to be 
more sensitive to this seven-day exploratory toxicological study. 
Although at a low dose of 5 mg/Kg/day was well tolerated, minimal 
nephrotoxicity signs were already observed in all eight animals 
tested. At higher doses (11 and 20 mg/Kg/day) histopathology 
revealed moderate to marked nephrotoxicity signs. Although the 
severity of renal lesions was higher for polymyxin B, the authors 
conclude that there was no significant safety margin in dog and 
further preclinical development was not pursued. This result also 
demonstrates that the broad in vitro difference in cytotoxicity 
observed in the PTEC assay in favor of 5x versus polymyxin B did not 
correlate with the in vivo safety test in dog. Thus, authors conclude 
that further work needed to be carried out to develop in vitro 





11.4 Monash FADDI analogs 
The Monash Institute of Pharmaceutical Sciences has also 
addressed the design of new polymyxin analogs focusing mainly in 
the hydrophobic domains of the molecule, residues 6 and 7 in the 
heptapeptide cycle and the fatty acid tail.  Compounds were 
prepared by total chemical synthesis on solid phase. A 
Fmoc/tBu/Dde scheme of protection on a trityl resin  was used. 
Macrocyclization took place in solution at high dilution conditions.  
Design of the analogs incorporated new hydrophobic moieties such 
as octylglycine (L-2-aminodecanoic acid) and biphenylalanine that 





FADDI-002  and FADDI-003 (Figure 7) yielded MIC of 2-4 μg.mL
-1
 
against polymyxin-resistant strains of P. aeruginosa (32 to >32 
μg.mL
-1
  for polymyxin B) and A. baumannii (2-16 μg.mL
-1
 in front of 
8-128 μg.mL
-1
 for polymyxin B). Against polymyxin sensitive strains, 
though, FADDI analogs were slightly less potent compared to 
polymyxin and colistin (MIC 1-4 μg.mL
-1
 compared to 0.5-2 μg.mL
-1
). 
Activity against Gram-positive bacteria was also reported and 
resistant strains of Staphylococcus aureus and Enterococcus faecium 










In an in vivo mouse lung infection model, FADDI-002 demonstrated 
better efficacy than colistin against a polymyxin resistant clinical 
isolate of P. aeruginosa.  Regarding safety and tolerability, no 
adverse effects were detected when a bolus dose of FADDI-002 was 
administered in rats (intravenous, 0.75 mg/kg) and mice 
(subcutaneous, 40 mg/kg). These in vivo preliminary results 
suggested that the FADDI series had at least a comparable 
tolerability to polymyxin in rodents. Further exploration led to 
substitution of position 7 with a threonine (analog FADDI-100), 
reminiscent of polymyxin M. FADDI-100 rendered a reduction of 
nephrotoxicity but when tested for potency in a collection of 250 P. 
aeruginosa isolates from Rempex-The Medicines Company, a MIC90 
of 32 μg.mL
-1
  was obtained.
216
 Finally, FADDI-287, a polymyxin E3 
analog with position 7 substituted by acid L-2-aminobutanoic (Abu) 
and Dap in position 3 (like analog 5x reviewed before), provided 
high potency (MIC90=1 μg.mL
-1
  in the same collection of P. 
aeruginosa isolates; MIC90=0.5 μg.mL
-1
 against 210 A. baumannii 
isolates). In vivo kidney histopathology in mouse model (dose at 12 
mg base/Kg, subcutaneously, every 2h x 6) showed much lower 
level of nephrotoxicity (mild acute tubular damage with tubular 
dilation) than polymyxin B (severe acute tubular damage and 




11.5 Queensland analogs 
Cooper’s group at the University of Queensland has been involved 
in the design and preparation of polymyxins and octapeptins. In an 
article by Gallardo-Godoy and coworkers, they performed a 
systematic activity-cytotoxicity study involving the preparation of 
32 analogs probing eight of the amino acid positions in polymyxin 
(Figure 8).
217
 Compounds were prepared by solid-phase chemical 
synthesis following a Fmoc/tBu/allyl scheme of protection on DHP 
polystyrene resin (3,4-Dihydro-2H-pyran-2-yl-methoxymethyl 
polystyrene) with side chain anchoring of the C-terminal threonine. 
Selective Dab modification was also achieved with the use of ivDde 
(1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)isovaleryl) protecting 
group when necessary. 
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Figure 8: Chemical structure of University of Queensland analogs 
(Aa corresponds to the side chain of the indicated amino acid). 
 
MIC results confirmed that more lipophilic side chains at positions 
6/7 improved activity against polymyxin-resistant strains but 
increased cytotoxicity in mammalian cells. Substitution of the Dab 
residues rendered different behavior depending on the position. 
Dab-5 and Dab-9 could not be replaced without severely affecting 
potency, while Dab-8, Dab-3 (substituted by Gly, Thr, D-Dab or D-
Ser, the last two reminiscent of polymyxins A, D, S or P) and Dab-1 
tolerated some substitutions. 
 
Another interesting result of the study was the nephrotoxicity 
predictive potential of in vitro cytotoxicity tests, an issue that was 
also discussed at Pfizer's work with analog 5x.
214
 Polymyxin B and 
colistin cytotoxicity were tested using cell lines HepG2 (hepatocyte 
carcinoma cells) and HEK293 (embryonic kidney cells). Results 
showed an apparent lack of toxicity (CC50 >300 μM) whereas in 
primary renal cell assay measuring LDH (Lactate Dehydrogenase) 
and GGT (Gamma Glutamyl Transferase) release, toxicity was clearly 
evidenced (CC50 of 23-177 μg/mL).
217
 An opposite behavior was 
observed with analog 14 of the series that yielded some toxicity 
readout in cell lines (287-296 μM) while in primary cultures gave a 
CC50 of >128 μg/mL.  
 
11.6 Northern Antibiotics analogs 
The team of Vaara at Northern Antibiotics in Helsinki has described 
a series of polymyxin analogs carrying only the three Dab residues. 
Compounds are obtained by substituting one or two of the Dab 
residues by D-Thr, D-Ser or Abu (2-aminobutanoic acid) amino 
acids, shortening the length of the linear tripeptide moiety of 
natural polymyxin, or both. The reason for this design lies in the fact 
that reducing the cationic character by eliminating some of positive 
charges in the molecule may also lead to a reduction in 
nephrotoxicity (Figure 9). Compounds of this family have direct 
antimicrobial activity (NAB739 NAB815) or sensitizing activity with 
other antibiotics (NAB741 and NAB7061). Analogs were synthesized 
following conventional solid phase chemical methods using a 
Fmoc/Bzl/Boc strategy of protection. Cyclization was carried out in 
solution.
16
 Analog NAB739 is based on polymyxin B but the N-
terminal lipotripeptide has been substituted by an octanoyl-Thr-
DSer segment. NAB739 exhibited good antimicrobial potency 
against Enterobacteriaceae comparable to the one of polymyxin B.  
 
 
Figure 9: Chemical structure of Northern Antibiotics analogs (Aa 
corresponds to the side chain of the indicated amino acid).  
 
Against E. coli, a concentration of 1 µg/mL of NAB739 inhibited 
growth in 74.5% of the strains while polymyxin B inhibited 84.3% of 
the strains in the same conditions. Against K. pneumoniae, the 
values of MIC90 for NAB739 and polymyxin B were 2 and 1 µg/mL, 
respectively. However, NAB739 was not so active against A. 
baumannii (MIC90 was 8 µg/mL, four-fold that of polymyxin B), P. 
aeruginosa (MIC90 was 16 µg/mL, eight-fold) and polymyxin-
resistant strains.
218,219
 In addition to antibacterial activity,  NAB739 
displayed  sensitizing activity at subinhibitory concentrations, 
facilitating the penetration of other antibiotics into bacterial cells. 
Against A. baumannii  and at a concentration of 0.5 μg/mL, NAB739 
had synergistic activity and reduced the MIC of rifampicin (from 4–
12 to 0.05–0.1 μg/mL), clarithromycin (from 6–8 to 0.5 μg/mL) and 
vancomycin (from 256 to 3 μg/mL).
220-222
 Cytotoxicity of NAB739 
proved to be 26-fold less toxic than polymyxin B in HK-2 (human 
renal proximal tubular) cells with a CC50 of 337 and 13 µg/mL, 
respectively (colistin's was 45 µg/mL). In permeabilized 
(electroporated) LLC-PK1 (porcine renal proximal tubular) cells, 
polymyxin B induced necrosis at 0.016 mM (ca 20 µg/mL), some 8-
fold lower than that for NAB739. NAB739 was found to be effective 
in treating E. coli peritoneal infection in mice (dosed at 1 mg/Kg 
twice).
223
 Recently a new analog NAB815 has been reported, 
presenting MIC90 values 2-fold less active against E. coli and K. 
pneumoniae and 2-fold more active against A. baumannii than 
NAB739 (both overall less active than polymyxin B). However, in 
vivo tests have shown that both NAB815 and NAB739 are better 
tolerated than polymyxin B in cynomolgus monkeys. In fact, a very 
significant portion of the dose of NAB815 and NAB739 is excreted 
into urine within 8 h after an intravenous infusion.
224
 Further 
studies will reveal their potential use in the clinic. 
 
Sensitizers, although sometimes devoid of intrinsic antimicrobial 
activity, retain the ability to permeabilize the outer membrane of 
Gram-negative bacteria. Polymyxin nonapeptide, a truncated 
version of polymyxin, is a long time kown paradigm example: it is 
able to increase susceptibility of E. coli and other Enterobacteriacea 
to some antibiotics, particularly lipophilic and amphiphilic ones, up 
to 100-fold times, at even low concentrations (1-3 μg/mL). In 
addition, since it lacks the N-terminal fatty tail, it is less 
nephrotoxic.
221
 NAB741 and NAB7061 are analogs of polymyxin B 
and NAB739, but their N-terminal lipopeptide segments are acetyl-
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Thr-DSer and octanoyl-Thr-Abu, respectively, thus carrying only 
three positive charges. Both compounds are devoid of direct 
antibacterial activity but are able to potentiate the 10- to 2000-fold 
the activity of hydrophobic antibiotics (e.g. macrolides, rifampicin) 
or large amphiphilic antibiotics (e.g. vancomycin) against 
Enterobacteriaceae and A. baumannii. 
 
The synergistic activity of NAB7061 has been also proven in vivo, in 
a mice model of E. coli peritoneal infection. Similarly,  the 
combination of NAB7061 (dose 5 mg/kg) and erythromycin (10 
mg/kg) was also effective.
220
 NAB741 has recently proceeded into 
preclinical studies, renamed as SPR741 due to an in-license 
agreement with Spero Therapeutics.
225
 SPR741 showed low 
nephrotoxicity in vivo in cynomolgus monkey and rat models. Only 
minimal tubular degeneration was observed at a dose of 60 
mg/Kg.day in monkey.
226
 SPR741 will enter phase I clinical trial 
(double-blind, placebo-controlled, ascending dose, multi-cohort 





11.7 Cantab analogs 
Cantab Anti-Infectives has generated a series of polymyxin analogs 
focusing on the modification of the N-terminal fragment (Figure 
10). Actually, the preparation of compounds was performed from 
either polymyxin nonapeptide (tetra-Boc protected) obtained from 
natural polymyxin B by enzymatic treatment with papain or from 
polymyxin heptapeptide obtained from the penta-Boc protected 
polymyxin by treatment with savinase in acetonitrile-water 
mixture.
228-231
 Carboxylic acids to be coupled to the corresponding 
peptides were obtained from commercial sources or prepared in 
house. Some analogs (example 50 in Brown’s patent)
229
 were also 
prepared by conventional Fmoc solid-phase chemistry and cyclized 
in solution. Amino acyl moieties in some analogs had the aminoalkyl 
side chain of natural Dab 1 embedded in piperazine (analog CA824) 
or piperidine (CA 900) rings.  MIC90 of the three selected analogs 
CA900, CA824 and CA1049 gave similar or slightly better values 
than polymyxin B against typical Gram-negatives such as E. coli 
(0.125 vs 0.25 μg/mL for polymyxin B), A. baumannii (0.25-2 vs 1 
μg/mL), P. aeruginosa (1 vs 8 μg/mL) and K. pneumoniae (0.25 vs 
0.5 μg/mL). CA900 gave particularly good activity against A. 
baumannii, with a MIC90 of 0.125 μg/mL compared to the one of 
polymyxin (1 μg/mL). All three analogs were less cytotoxic in HK-2 
cell cultures (TC50 of 64, 148 and 167 μg/mL for CA 1049, 824 and 




In vivo efficacy was carried out with CA824 analog. In neutropenic 
mouse lung infection models, the antibacterial activity of CA824 
proved to be superior to polymyxin B against A. baumannii NCTC 
13301 and P. aeruginosa ATCC 27853 while in a mouse thigh 
infection model, the antibacterial activity of CA824 against the 
same A. baumannii strain was comparable.
233
 In January 2017,  
Spero Therapeutics acquired the assets developed by Cantab Anti-
Infectives to the owner Pro Bono Bio Ltd to bring the program 




11.8 Scaffold modified polymyxins 
Throughout this review we have seen that antimicrobial potency in 
polymyxins tends to correlate with toxicity. Both antimicrobial 
activity and toxicity side effects in mammalian cells seem to be 
associated to the amphipathic nature of the molecule (hydrophobic 
and polycationic). 
 
Figure 10: Chemical structures of Cantab analogs 
 
 
A reasonable approach to break this parallel activity could be the 
modification of the backbone of the structure, a fact that is also 
compatible with the substitution of the amino acids of the 
sequence or the fatty acid to modify the periphery of the molecule. 
This idea would link to what it is known as soft drug design, which 
essentially means integrating metabolism considerations into the 
drug design process.
235
 With this purpose, different chemical units 
or bonds are introduced into the scaffold to help metabolism to 
deactivate and detoxify the molecule once it has exerted its desired 
antimicrobial activity. 
 
In section 10.1., we have seen that polymyxin B and colistin are 
quite stable molecules. They seem not to be fully metabolized or 
detoxified in the kidney and accumulate in the renal cortex despite 
the fact that the majority of kidney’s drug metabolizing and 
detoxification enzymes are located in the proximal tubule (see 
below). For instance, B- esterases, peptidases and oxidorreductases 
are localized relatively in high amounts in proximal tubule kidney 
cells. 
 
Two examples of polymyxin analogs have been recently described 
in the literature  that contain modifications in the peptide backbone 
designed to aid in the metabolization and prevent accumulation in 
kidneys, and hence, potentially reduce toxicity: ester-containing (i. 
e. depsipeptide) analogs of polymyxin (MicuRx and Barcelona)
236,237
 





11.9 MicuRx analogs 
MicuRx has described analogs that incorporate ester, carbamate 
and phosphate/phosphonate/phosphoramide type of bonds within 
the N-terminal part of polymyxin (Figure 11).
236
 The introduction of 
esters within polymyxin has been described before.
229,238
  
Compounds were prepared by semisynthesis from polymyxin 
nonapeptide and adding conveniently protected Fmoc/tBu amino 
acids, such as Boc-protected homoisoserine (L-2-hydroxy-4- 
aminobutanoic acid), Fmoc-Dab(Boc)-OH or other acids,  by means 
of standard coupling techniques and reagents. 
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Figure 11: Chemical structure of MicuRx analogs and the hydrolysis 
products rendered by esterases 
 
 
Some fifty polymyxin analogs were prepared. Analogs 12 and 18 
offered antibacterial activity comparable to polymyxin B and had an 
ester bond embedded in the fatty acid moiety. They both yielded 
MIC of 2 μg/mL against E. coli (vs 2-4 μg/mL for polymyxin B), 2 and 
4 μg/mL, respectively against P. aeruginosa (vs 2-4  μg/mL) and 2 
and 4 μg/mL, respectively against K. pneumoniae (vs 2-4  μg/mL). 
Cytotoxicity of both analogs in human HK-2 cells was lower (IC50 > 




In vivo efficacy of analogs 12 and 18 in E. coli septicemia, P. 
aeruginosa thigh infection, and P. aeruginosa lung infection mouse 
models proved to be comparable to the efficacy results obtained for 
polymyxin B. A reduction of in vivo nephrotoxicity in rat model was 
observed for both in comparison with polymyxin B according to the 
low levels of urine biomarker NGAL (see section 11 before). Finally, 
stability in human plasma demonstrated that 66-67% of the original 
ester compounds 12 and 18 remained non-hydrolized after 1 h (at 4 




11.10 Barcelona analogs 
The University of Barcelona has described analogs of polymyxin 
where the amide bond between the γ–amino group of Dab4 and 
the C-terminal carboxy group of Thr10 has been replaced with a 
disulfide bond (Figure 12).
91
 This replacement is isosteric and 
implies the substituition of those amino acids with cysteines with an 
appropriate configuration of the α-carbon (L-cysteine in position 4 
and D-cysteine in 10). The disulfide link may provide polymyxin 
analogs with sufficient stability to reach the infectious target in 
vivo. However, in an eventual accumulation and uptake by renal 
cells, the disulfide bond may be broken thus opening up the cyclic 
heptapeptide due to the reducing intracellular environment 
(reduced glutathione and oxidorreductases) that could facilitate 
peptide proteolysis and potentially lower renal toxicity. In this 
respect, detoxification of xenobiotics in kidney is carried out by 
metabolizing enzymes that are involved, for instance, in the 
conjugation of glutathione, glucuronic acid, or sulfate. These 
enzymes, including cytochrome P-450, are mainly localized in 








In particular, proximal tubular cells exhibit a high activity in 
glutathione redox cycle enzymes, such as glutathione disulfide 
reductase, GSH peroxidases, and GSH S-transferase. The 
intracellular concentration of glutathione in proximal tubular cells is 
around 2-5 mM whereas in the lumen is at least two orders of 





Furthermore, in an in vivo study in rat dealing with the metabolism 
and retention of octreotide (a marketed disulfide cyclic peptide also 
containing two D-amino acids)
91
 in kidney and liver, metabolites of 
radiolabeled octreotide were shown to be decyclized (linear) 
products by reduction of the disulfide bond to cysteine and 




All this data supports the use of the disulfide bond as a tool to 
modulate the stability of the polymyxin scaffold, facilitate 
metabolization and reduce accumulation in kidney.  In fact, the use 
of disulfide bonds in drugs should not be seen as exceptional. There 
are several peptide drugs in the market containing disulfide bonds, 
such as octreotide, lanreotide or vapreotide (analogs of 
somatostatin that consist of a disulfide cyclic octapeptide), insulin, 
linaclotide (for inflammatory bowel syndrome),  ziconotide 
(treatment of pain), pramlintide (for type II diabetes), atosiban 
(inhibitor of the hormones oxytocin and vasopressin), neseritide 
(for acute decompensated congestive heart failure), romidepsin 
(anticancer agent used in cutaneous T-cell lymphoma), and 
peginesatide (treatment of anemia associated with chronic kidney 
disease). 
 
Preparation of the analogs was carried out by Fmoc/tBu solid phase 
chemical synthesis. Cyclization by means of disulfide bond 
formation was performed at high dilution conditions in plain water 
and dimethylsulfoxide solvent, with no other reagents. Antibacterial 
activity comparable to polymyxin B was achieved, including 
resistant and multi-drug resistant strains.   Analogs 38 and 39 
yielded both MIC of 2 and 4 μg/mL, respectively against E. coli (vs 1 
μg/mL for polymyxin B), 1 μg/mL against P. aeruginosa (vs 2  μg/mL, 
polymyxin B). Against resistant strains, Analogs 38 and 39 yielded 
both MIC of 0.5 and 0.5-1 μg/mL, respectively against E. coli (vs 
0.25-0.5 μg/mL for polymyxin B) and 0.5-4 μg/mL against P. 
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aeruginosa (vs 1-2  μg/mL, polymyxin B).
91
 Whatsmore, analog 39 
was also active against Gram-positive bacteria S. aureus and 
Enterococcus faecalis, rendering comparable MIC to those of 
daptomycin and vancomycin. Analog 38 has also demonstrated 
synergistic and antibiofilm activities with imipenem in a 
imipenen-resistant strain of P. aeruginosa.
242
 Finally, an in vivo 
acute toxicity test by subcutaneous administration performed on 
CD-1 mice with analog 38, the LD50 obtained (283 mg/kg) was 
clearly superior to the one reported for polymyxin B (59.5 mg/kg).
91 
 
Further in vivo tests (pharmacokinetic studies, full toxicity and 
efficacy) are ongoing and will be reported in due course. 
 
12. Conclusions and Perspectives 
 
The emergence of multi-drug resistant Gram-negative bacteria will 
need of all efforts (antimicrobial chemical design, medicinal 
chemistry, microbiology, pharmacology, development, clinical 
studies, rational use of antibiotics) to control this new health 
challenge. 
 
The research and development of alternative antimicrobial agents is 
a plausible option to tackle the resistance problem and the 
“antibiotic discovery void” since the late 1980s. Unfortunately, in 
the field of polymyxins, only a single candidate, CB-182,804 has 
progressed to a clinical phase but was finally discontinued. 
Recently, a new polymyxin molecule, SPR741, has been announced 
to proceed to clinical phases albeit as a potentiator, not as an 
antimicrobial per se.
227
 Hence, much effort and new approaches are 
still needed.   
 
The design, discovery and development of new chemical entities, 
particularly those with new scaffolds or acting by new mechanism 
of action will certainly play a fundamental role. Furthermore, 
advances in the understanding at the molecular level of the 
mechanism of polymyxin toxicity will provide new insights on how 
to design new molecules with better therapeutic indexes. In this 
sense, the incorporation of metabolism considerations into the drug 
design process is a promising new line. New challenges will rise, 
though, as these new chemical units need to keep a balance 
between stability to reach the target and exert the desired 
antimicrobial activity in vivo and later facilitate metabolization and 
detoxification of the molecule thus preventing unwanted side 
effects. 
 
In the short run, natural polymyxin B/colistin and colistimethate will 
continue to be used as last-line therapeutic option due to the 
scarcity of antibiotics against MDR Gram-negative bacteria. 
Nevertheless, recent pharmacological progress and understanding 
of the mechanism of action and toxicity in polymyxins provides 
clinicians with valuable information for optimizing their use in 
patients (dosage, combinations, nephrotoxicity, biomarkers).
243
 Still 
a large amount of work is necessary for instance to clarify the 
advantage of antibiotic combinations with polymyxins. In this sense, 
clinical trials to compare colistin monotherapy and the combination 




We hope that the next generation of polymyxins will become 
satisfactory therapeutic tools for the treatment of infections caused 
by multi-drug resistant bacteria. 
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The rise of bacterial pathogens with acquired resistance to almost all available antibiotics is becoming a serious public health 
issue. Polymyxins, antibiotics that were mostly abandoned a few decades ago because of toxicity concerns, are ultimately 
considered as a last-line therapy to treat infections caused by multi-drug resistant Gram-negative bacteria. This review 
surveys the progress in understanding polymyxin structure, chemistry, mechanisms of antibacterial activity and 
nephrotoxicity, biomarkers, synergy and combination with other antimicrobial agents and antibiofilm properties. An update 
of recent efforts in the design and development of a new generation of polymyxin drugs is also discussed. A novel approach 
considering the modification of the scaffold of polymyxins to integrate metabolism and detoxification issues into the drug 
design process is a promising new line to potentially prevent accumulation in kidney and reduce nephrotoxicity. 
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1. Introduction 
Polymyxins are a group of antimicrobial cyclic lipopeptides 
discovered in 1947.1-3 They are produced by fermentation of strains 
of Paenibacillus polymyxa (formerly known as Bacillus polymyxa). 
Polymyxins consist of a heterogeneous mixture composed of up to 
30 closely related lipopeptides (Table I).4-7 The term “polymyxin” is 
accepted as the general name for this class of antibiotics produced 
by P. polymyxa. Polymyxin B and colistin (polymyxin E) are the most 
known members of this family as they were commonly used as 
antibiotics in hospitals from late 1950s to late 1970s, approximately. 
Then, they were gradually withdrawn from the clinical practice due 
to toxicity issues such as adverse neurological effects and most 
importantly, nephrotoxicity concerns. In addition, novel 
aminoglycosides (gentamicin) and second- and third-generation 
cephalosporins showing less toxic side effects became available.8 
However, the emergence of Gram-negative bacteria that are 
resistant to almost all classes of available antibiotics has resulted in 
the rescue of polymyxins as a last resort for patients whose other 
treatment options were limited.  
Antibiotic resistance is becoming a serious public health issue. In 
the USA, for instance, at least 2 million people are infected by 
antibiotic-resistant bacteria and at least 23,000 people die each year 
as a direct consequence.9,10  A similar situation is taking place in 
Europe. 11,12  The WHO has recently issued a list of the most critical 
pathogenic bacteria for which new antibiotics are urgently needed:  
carbapenem-resistant strains of Acinetobacter baumannii, 
Pseudomonas aeruginosa, and Enterobacteriaceae.13  
Polymyxin B and colistin are now used as a last-line therapy to 
treat infections caused by multi-drug resistant bacteria such as P. 
aeruginosa, A. baumannii, Klebsiella pneumoniae, and Escherichia 
coli . These bacteria are part of the so-called ESKAPE bacteria, thus 
nicknamed by the Infectious Disease Society of America that  
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Faculty of Chemistry, University of Barcelona. E-mail: frabanal@ub.edu 
 b Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, 
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Table 1: Structure of naturally occurring polymyxins B and E (colistin), 
clinically relevant members of the polymyxin family§ 
Polymyxin Fatty acyl tail Aa 6 Aa7 
B1 (S)-6-methyloctanoyl D-Phe Leu 
B1-Ile (S)-6-methyloctanoyl D-Phe Ile 
B2 6-methyheptanoyl D-Phe Leu 
B3 octanoyl D-Phe Leu 
B4 heptanoyl D-Phe Leu 
B5 nonanoyl D-Phe Leu 
B6 3-hydroxy-6-methyloctanoyl D-Phe Leu 
E1 (S)-6-methyloctanoyl D-Leu Leu 
E2 6-methyheptanoyl D-Leu Leu 
E3 octanoyl D-Leu Leu 
E4 heptanoyl D-Leu Leu 
E7 7-methyloctanoyl D-Leu Leu 
E1-Ile 
(circulin A) 
(S)-6-methyloctanoyl D-Leu Ile 
E1-Val (S)-6-methyloctanoyl D-Leu Val 
E1-Nva (S)-6-methyloctanoyl D-Leu Nva 
E2-Val 6-methyheptanoyl D-Leu Val 
E2-Ile 6-methyheptanoyl D-Leu Ile 
E8-Ile 7-methylnonanoyl D-Leu Ile 
 
Table 2: Structure of additional naturally occurring polymyxins§  
Polymyxin Fatty acyl tail Aa3 Aa6 Aa7 Aa10 
A1 6-methyloctanoyl D-Dab D-Leu Thr Thr 
A2 6-methylheptanoyl D-Dab D-Leu Thr Thr 
C1 6-methyloctanoyl Dab Phe Thr Thr 
C2 6-methylheptanoyl Dab Phe Thr Thr 
D1 6-methyloctanoyl D-Ser D-Leu Thr Thr 
D2 6-methylheptanoyl D-Ser D-Leu Thr Thr 
F1 6-methyloctanoyl (Dab x5, Thr, Leu x2, Ser, Ile) 
F2 6-methylheptanoyl (Dab x5, Thr, Leu x2, Ser, Ile) 
M1 6-methyloctanoyl Dab D-Leu Thr Thr 
M2 6-methylheptanoyl Dab D-Leu Thr Thr 
S1 6-methyloctanoyl  D-Ser D-Phe Thr Thr 
T1 6-methyloctanoyl Dab D-Phe Leu Leu 
T2 6-methylheptanoyl Dab D-Phe Leu Leu 
PMB1 6-methyloctanoyl D-Dab D-Phe Thr Thr 
PMB2 6-methylheptanoyl D-Dab D-Phe Thr Thr 
P1 6-methyloctanoyl  D-Dab D-Phe Thr Thr 
P2 6-methylheptanoyl  D-Dab D-Phe Thr Thr 
§ The reader may find nomenclatures such as "iso" and  "ante-iso" fatty acids 
in the literature. For instance, isooctanoic acid, i-C8 corresponds to  
6-methylheptanoic acid. Anteisononanoic acid, a-C9, corresponds to 6-
methyloctanoic acid and may appear in two different configurations, R or S, 
since a stereocenter is present in carbon 6. The configuration of this 
stereocenter is expected to be S as the branch-chain fatty acid synthesizing 
system starts in the case of anteiso-fatty acids from the -ketoacid of 
isoleucine as primer. Isoleucine has an S configuration in carbon 3, in its 
sidechain. 
 
has proposed to pursue a global commitment to develop 10 new 
antibacterial drugs by 2020 (the 10 x '20 Initiative).  “ESKAPE” stands 
for the initials of the above mentioned Gram-negative bacteria 
together with Gram-positive Enterococcus faecium and 
Staphylococcus aureus.9 
 
Figure 1: Polymyxin B1 as an example of the general structure of 
polymyxins. Amino acid positions are numbered from 1 to 10. 
 
The objective of this review is to gather and analyze the 
background in the field of polymyxins, highlighting  the efforts and 
new approaches carried out by different groups worldwide toward 
the design and development of new polymyxin-based compounds 
potentially capable of overcoming the current drawbacks of the 
natural compound, particularly, nephrotoxicity. Other fundamental 
reviews in the field of polymyxins have been published in the last 
years. As the present manuscript will mainly but not only concentrate 
in the last decade achievements and new approaches, the reader is 
also addressed to reviews by Vaara, Velkov&Li, Brown&Dawson for 
a previous background in the area.14-17  
2. Naturally occuring polymyxins 
The Paenibacillus genus (previously included in the genus 
Bacillus) comprises tenths of species that are facultative anaerobic 
and endospore-forming bacteria. In particular, strains of 
Paenibacillus polymyxa thrive in the plant rizhosphere, are capable 
of fixing nitrogen, suppress some plant diseases and promote a 
healthy growth in plants, such as crops and trees. Hence, P. polymyxa 
strains are used as an effective alternative to the chemical control 
against a wide set of plant pathogenic fungi and bacteria. Polymyxins, 
including colistin and circulin, are the main class of peptide 
antibiotics produced by most strains of P. polymyxa although other 
compounds are produced as well. Other strains produce peptides 
such as polyxins, polypeptins or fuaricidins.18 
 
The general structure of polymyxins consists of a cyclic heptapeptide 
unit (amino acids 4-10) and a lipotripeptide that bifurcates from the 
fourth amino acid of the sequence (Figure 1). The lipid unit capping  
the N-terminal amino acid is a linear or branched fatty acyl moiety, 
that together with amino acids in the 6th and 7th position define the 
hydrophobic features of the molecule. The rest of amino acid 
residues are polar (L-threonines) and amino-containing basic 
residues (2,4-diaminobutanoic acid) that provide polymyxins with its 
polycationic nature at physiological pH. Polymyxins are secondary 
metabolites generated by non-ribosomal peptide synthetase enzyme 
complexes. Hence, they contain non-proteinogenic amino acids as 
well (not present in regular coded proteins) such as the above 
mentioned 2,4-diaminobutanoic acid, D-phenylalanine or D-Leucine. 
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The first polymyxins discovered were reported almost 
simultaneously by three different teams in 1947: Benedict and 
Langlykke,1, Stansly and coworkers2 and Ainsworth and coworkers.3 
Ainsworth called the antibiotic "aerosporin" since it was obtained 
from Bacillus aerosporus which later was found to be B. polymyxa, 
essentially the same studied by Benedict and Langlykke. The 
antimicrobial "aerosporin" is now known as polymyxin A, whereas 
the so-called “polymyxin” described by Stansly corresponds to 
polymyxin D. Further investigations by Brownlee and Bushby 
managed to isolate a third type of polymyxin, which was named 
polymyxin B, and later, polymyxins C and E were found. Polymyxins 
A, B, C, D and E showed similar antibacterial activity, but an in vivo 
assay of nephrotoxicity in Wistar rats by estimating the total protein 
excreted in the urine indicated a striking increase of proteinuria for 
polymyxins A, C and D but not for polymyxins B and E.19  
 
In parallel, Koyama described in 1950 the isolation of an antibiotic 
from a culture broth of a new strain they named Bacillus polymyxa 
var. colistinus (Aerosporus colistinus).20 The new compound was 
called colistin, and chemical determination proved it to be cyclic and 
share an amino acid composition qualitatively identical to that of 
polymyxin E described by Brownlee.21 
 
In 1948, Tetrault and coworkers isolated another antibiotic peptide 
that named circulin as it was produced by Bacillus circulans. It was 
found to share a similar composition to the one of polymyxins known 
so far. It was also active against Gram-negative bacteria. In the 
following years, other members of the family were discovered, such 
as polymyxin M found in the soil of Moscow by Khokhlov and 
coworkers.21,22 More recently, Martin and coworkers have isolated 
mattacin, a cyclic lipodecapeptide produced by Paenibacillus 
kobensis M and found by structure elucidation to be identical to 
polymyxin M.23 
 
Polymyxin P, described for the first time in 1969, has been recently 
found to be the main compound produced by P. polymyxa M-1. 
Polymyxin P suppressed the growth of phytopathogenic 
Enterobacteriaceae bacteria Erwinia amylovora Ea 273, and E. 
carotovora, the causative agents of fire blight (in apples and pears) 
and soft rot, respectively. Hence, it has been proposed as an 
alternative of chemical bactericides to control these and other plant 
diseases caused by Gram-negative bacteria.24,25 
 
Other polymyxins, such as polymyxin S1 and T1 were isolated from 
P. polymyxa Rs-6 and E-12, respectively. Polymyxin T1 was found to 
be active not only against Gram-negative bacteria but also against 
Gram-positive bacteria, a characteristic shared with polymyxin 
M.25-29 Polymyxin F, produced by Bacillus circulans ATCC 31228, has 
also been described.30 Similarly, polymyxin C has also been reported 
(see above) but apparently, has not been subjected to detailed 
structural studies. 28,31,32 
 
The last members of the polymyxin family described so far were 
diasteromers of polymyxin B, named PMB1 and PMB2.33 They were 
produced by P. polymyxa PKB-1 and had a D-Dab amino acid in 
position 3 rather than the usual L-Dab. Their sequences were 
elucidated by high-resolution mass spectrometry, MS/MS 
sequencing, and the stereochemistry, by chiral gas chromatography.  
  
Finally, it is worth mentioning a family of natural products called 
octapeptins, first reported in the mid 1970's.22 They are closely 
related to polymyxins as both families share a similar structure. They 
consist of a cyclic polycationic peptide sequence, containing a high 
percentage of 2,4-diaminobutanoic acid and a fatty acyl tail bound 
through an amide linkage. However, octapeptins contain eight amino 
acid residues as it may be deduced from its name,  with a single 
exocyclic amino acid stemming from the cycloheptapeptide moiety. 
A review on octapeptins has recently been published in this journal 
so the reader is kindly referred to this document for further 
information.34 
3. Antimicrobial profile  
Polymyxins are narrow-spectrum antibiotics since they are only 
active against Gram-negative bacteria including multi-drug resistant 
(MDR) strains. This includes some non-fermenting bacteria such as P. 
aeruginosa and Acinetobacter spp. and some members of the 
Enterobacteriaceae family, Escherichia spp, Klebsiella spp, 
Enterobacter spp, Citrobacter spp, Salmonella spp, Shigella spp and 
Haemophilus spp, and Pasteurella spp. However, Proteus spp, 
Burkholderia spp, Serratia spp (i. e. Serratia marcescens) and 
Moraxella spp (i. e. Moraxella catarrhalis) and genera Brucella, 
Neisseria, Chromobacterium and Providencia, have intrinsic 
resistance to polymyxins.35 Finally, it has been reported that 
polymyxin E was found to be active against some mycobacterial 
species, e.g. Mycobacterium xenopi, M. intracellulare, M. 
tuberculosis, M. fortuitum, M. phlei and M. smegmatis.36,37 
Polymyxin B also exhibited activity against Cryptococcus 
neoformans  fungus.38 
4. Commercially available polymyxins 
Since polymyxins are manufactured by fermentation procedures, 
they have a heterogeneous composition. They contain several 
structurally related components such as isomers and homologous 
compounds (Table 1). For instance, the major constituents of 
polymyxin B obtained from P. polymyxa are the related polymyxins 
B1, B2, B3 and B1-Ile, differing only in the fatty acyl moiety and the 
amino acid in position 7 (Leu or Ile). Their composition and 
antibacterial activity have been recently studied in detail. A typical 
proportion of components in polymyxin B would be ca 70-74% of the 
B1 type, 13-16 % of B2, 3-5% of B3 and around 8-9 % of Ile-B1.39,40 
The activity of some of these components have been assessed 
individually in strains of P. aeruginosa, A. baumannii and K. 
pneumoniae including multi-drug resistant isolates. The results of 
antimicrobial activity measured by means of their MIC (minimal 
inhibitory concentration) showed differences within the variability 
generally accepted for such a kind of assays. Apparently, the minor 
structural differences (length of the fatty acid tail and compound 
isomers)  among the components did not affect much their in vitro 
potency.40,41  Nevertheless, it is worth mentioning that one of the 
minor components, polymyxin B3, showed higher activity than the 
rest against P. aeruginosa, E. coli and K. pneumoniae 
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while the compound  B1-Ile was more potent against A. baumannii.  
In the same study, synergism between the different members of the 
polymyxin B mixture following checkerboard analyses was explored. 
The tests revealed that the combination of polymyxins B3 and B1-Ile 
met the criteria for synergy against Enterobacteriaceae whereas the 
major components polymyxin B1 and B2 showed a low probability of 
synergy when combined.42 
 
Regarding the pharmacokinetics of individual polymyxin B major 
components, no considerable differences were detected among 
them when tested in the rat animal model and in humans. In fact, it 
has been proposed as a reasonable approach to use the combined 
concentration values of the individual polymyxin components in 
pharmacokinetic studies to estimate overall drug exposure to 
polymyxin B.43 
 
In another study comparing polymyxin B and colistin in the rat model, 
the individual major components of polymyxin B (B1 and B2) and 
colistin (A and B) yielded similar pharmacokinetic parameters such as 
clearance, volume of distribution, elimination half-life, and urinary 
recovery. Notwithstanding that, colistin A (polymyxin E1) and colistin 
B (polymyxin E2) displayed lower protein binding in rat plasma 
compared to polymyxins B1 and B2. 
 
In relation with the accumulation of the individual products (B1, B1-
Ile, B2+B3) in kidney, a fact that correlates with nephrotoxicity (see 
section 10 below), the relative proportions of the components 
present in the renal tissue at 48 h were found to be comparable to 
the concentrations in the USP (United States Pharmacopeia) mixture 
indicating no preferential accumulation of any of the 
components.44,45 
 
Commercial polymyxin B is available in the sulfate form either for 
parenteral (intravenous and intramuscular), topical (ophthalmic and 
otic instillation), and intrathecal use (in cases of MDR Gram-negative 
caused meningitis). The dosage of intravenous polymyxin B is  
generally 1.5-2.5 mg/kg/day (15.000-25.000 IU/kg/day; 1 mg of 
polymyxin B corresponds to ca 10.000 IU, International Unit), 
However, commercial formulations of polymyxin B are not always 
available in many countries of the world. Injectable polymyxin B and 
colistin formulations are available only in Brazil, Malaysia, Singapore 
and the USA while in Europe and Australia, colistimethate is the only 
parenteral formulation that can be found. For the treatment of eye 
infections caused by P. aeruginosa, 0.1-0.25% polymyxin B solutions 
(10.000 IU to 25.000 IU/ml) are recommended. Polymyxin B in 
combination with a local anaesthetic (i. e. lidocaine, procaine) can 
also be found for intramuscular administration, in eardrops, and 
ointments. Combination with hydrocortisone is also available for otic 
use.15,46  
 
Colistin has two commercially available forms: colistin sulfate and 
sodium colistimethate (sodium colistin methanesulfonate, CMS, 
Figure 2).47 Both contain different proportions of colistin A 
(polymyxin E1), and colistin B (polymyxin E2), which account for 
more than 80% of colistin, together with many other minor 
components.6 Colistin sulfate may be administered orally for bowel 
decontamination or topically as a powder for the treatment of 
 
Figure 2: Structure of sodium colistimethate and colistin A 
(polymyxin E1). Molecular weight of colistimethate is 1749.81 g.mol-1 
(C58H105N16O28S5Na5) while for the free base (devoid of sodium 
methylsulfonate derivatisation) it is 1169.48 g.mol-1 (C53H100N16O13). 
Hence, 1 mg of colistimethate corresponds to 0.67 mg of free base 
colistin (or 0.81 mg of colistin sulfate, assuming 2.5 mols of sulfate 
per mol of colistin) 
 
bacterial skin infections. Colistimethate is a prodrug of colistin. It is 
produced by the reaction of colistin with formaldehyde and sodium 
hydrogensulfite (see section 10 below). It is less toxic than colistin 
sulfate since it is polyanionic, but devoid of antimicrobial activity. It 
can be administered parenterally (intravenously, intramuscularly), 
intrathecally, intraventricularly or by inhalation (aerosolized, to treat 
respiratory tract infections caused by multidrug-resistant Gram-
negative bacteria, and cystic fibrosis). Colistimethate as a prodrug, 
slowly reverts to colistin although hydrolysis is not always 
complete.48,49 It has been reported that only a 31.2% of CMS is 
hydrolysed in vitro to colistin in 4 hours at 37°C in human plasma.50  
In vivo, even smaller proportions of colistimethate are converted to 
colistin.51 This has been attributed to the slow hydrolysis rate of 
colistimethate to colistin combined with a fastest rate of renal 
clearance. In fact, it is estimated that only ca 25% of colistimethate 
is converted to active colistin in patients with normal renal 
function.52   
 
Colistimethate  intravenous dosage in adult patients with normal 
renal function are different in Europe and USA. In Europe 
colistimethate doses are in general 4-6mg/kg (50.000-75.000 IU/kg 
daily; 1 mg of colistimethate corresponds to 12.500 IU). In France and 
Austria, it reaches values of 12mg/kg (150000 IU/kg/day). In the USA, 
the recommended dose is 2.5-5 mg/kg expressed in terms of colistin 
base, equivalent to 6-12 mg/kg of colistimethate, (75000-150000 
IU/kg).46,54 
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Examples of polymyxin drug brands approved by the FDA and 
present in the market include Pediotic®  (neomycin, polymyxin B 
sulfate and hydrocortisone suspension, USP,  for otic use), 
Polysporin®  (polymyxin B, zinc bacitracin and gramicidin; aerosol, 
topical, and ophthalmic), Neosporin® (polymyxin B, zinc bacitracin 
and neomycin triple ointment) and Polytrim® (polymyxin B sulfate 
and trimethoprim ophthalmic solution, USP). Colomycin® and 
Coly-Mycin® contain colistin methanesulfonate as the active 
principle (1-2 million units, for injection). Polymycin B sulfate 
(polymyxin B sulfate) was approved by the FDA in 2011 for the 
treatment of infections caused by resistant strains of P. aeruginosa, 
H. influenzae, E. coli, Enterobacter aerogenes, and K. pneumoniae by 
parenteral administration.32 
5. Mechanism of action  
Polymyxins have a narrow antimicrobial spectrum with selectivity for 
Gram-negative bacteria. This is because the first molecular target of 
these polycationic lipopeptides is the lipopolysaccharide (LPS), the 
main component of the outer membrane (OM) of Gram-negatives.  
The low permeability of the two-membrane cell envelope in Gram-
negative bacteria is the main reason for the low hit rate in the 
discovery of new antibiotics against this bacterial class.55 The outer 
membrane is an asymmetric bilayer of LPS in the outer monolayer, 
and a mixture of phospholipids in the inner. 56,57  LPS is composed of 
three domains: lipid A, central core oligosaccharide, and outermost 
O-antigen chain.58 Lipid A is the domain responsible for outer 
membrane thigh packing, and the principal target for polymyxins. It 
contains an N- and O-acylated diglucosamine bisphosphate 
backbone, and forms a highly packed structure. Although there are 
many variations among species, in polymyxin-sensitive bacteria LPS 
has several anionic charges, responsible for the strong electrostatic 
interactions with polycationic polymyxins. LPS molecules are bridged 
and partly neutralized by divalent ions Ca2+ and Mg2+, thus conferring 
a high rigidity and low permeability to the outer membrane.56,59 
The antimicrobial activity of polymyxins begins by competitive 
displacement of membrane-stabilizing divalent cations Ca2+ and 
Mg2+, thus causing a destabilization of the LPS layer and allowing 
insertion of the hydrophobic acyl chain of the antibiotic, which 
locates in the hydrophobic domain of lipid A.60,61 This causes an 
expansion of the LPS monolayer15,62 and results in disruption of the 
outer membrane permeability barrier, facilitating the entrance of 
polymyxin into the periplasmic space, a process of self-promoted 
uptake first described by Hancock.63,64 Binding to LPS is a required 
first step for antibacterial activity, but it is not enough. For example, 
deacylated polymyxin B nonapeptide, lacking the N-terminal acyl 
chain and Dab1 residue, is an extremely poor antibiotic, but is still 
capable of binding to LPS and preserving a significant OM-
permeabilizing action.14 This susceptibility explains the drastic 
sensitizing action of the nonapeptide, allowing other small molecules 
(such as conventional antibiotics) to cross the outer membrane.65 In 
addition, polymyxin resistance is related to lipid A modification with 
phosphoethanolamine and/or galactosamine, or to the complete 
loss of LPS, thus avoiding binding of polymyxins to the OM.66 
The interaction of PxB and PxB nonapeptide with LPS has been 
studied in detail at the molecular level, and involves hydrophobic as 
well as electrostatic interactions. The structure of PxB bound to LPS 
has been determined by NMR spectroscopy,67-70 and consists in an 
envelope-like fold of the peptide ring separating the polar/charged 
residues from the hydrophobic components, conferring an 
amphiphilic character to the structure. It is postulated that the β-turn 
structure is stabilized by hydrophobic interactions involving two 
hydrophobic domains on the lipopeptide DPhe6-L-Leu7 domain on 
the peptide ring, and the N-terminal fatty acid chain, with the 
aliphatic chains of lipid A.65,68 The electrostatic interactions between 
the positive side chains of Dab residues on PxB and two of the 
negative phosphate groups of the phosphorylated lipid A headgroups 
are essential for complex formation, whereas the hydrophobic 
interactions are responsible for insertion into the outer membrane 
hydrophobic core. The structure of PxB nonapeptide bound to LPS 
has been determined by tranferred nuclear Overhauser effect NMR 
and molecular dynamics,70 and is consistent with surface binding of 
the peptide, without insertion into the hydrophobic core of lipid A. 
This will explain the lack of antibiotic activity, since the nonapeptide 
will not reach the inner membrane.  
Once polymyxin has crossed the outer membrane, it must interact 
with the cytoplasmic or inner membrane in order to kill the 
bacteria.11 The inner membrane in Gram-negative bacteria is mostly 
composed of zwitterionic phospholipid phosphatidylethanolamine 
(PE) and anionic phosphatidylglycerol (PG) and cardiolipin (CL). All 
bacteria have at least a 15% of anionic lipids, but this can be either 
PG or CL or both.57 The same lipids are found in the inner layer of the 
outer membrane, although the proportions are different.71 The 
mechanism of bacterial killing is not related with membrane 
permeation, which takes place at concentrations well above the 
minimal inhibitory concentration.62,72,73 A threshold concentration of 
PxB is required on the membrane to form clusters that insert and 
form depolarizing ion-permeable pores, however dissipation of the 
pH gradient is not observed in E. coli after PxB treatment, and the 
bactericidal effect is expressed at lower concentrations and is not 
dependent on depolarization of the outer membrane.74 Although a 
mechanism of bacterial killing based on disruption of the physical 
integrity of the cytoplasmic membrane by pore formation or even a 
detergent effect are demonstrated for other AMPs,75 in the 
polymyxin family such effects only occur at high peptide/lipid ratios. 
 
A more likely mechanism of action has been described for polymyxin 
B that involves contact formation between the outer and inner 
membranes of Gram-negative bacteria,71,76 also seen in other 
antimicrobial peptides such as cecropins,77 and rBPI21.78 According to 
this model, once in the periplasmic space stoichiometric amounts of 
polymyxin will form contacts between the two enclosed 
phospholipid interfaces, and promote a fast and selective exchange 
of anionic phospholipids. The resulting changes in the membrane 
lipid composition trigger an osmotic imbalance that leads to bacterial 
stasis and cell death.79 Biophysical studies using model membranes 
have demonstrated that at the concentrations around the MIC, PxB 
and colistin induce the apposition of anionic vesicles with a 
composition that mimics the bacterial membrane, and the formation 
of functional vesicle-vesicle contacts.80 These contacts support a fast 
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and selective exchange of phospholipids exclusively between the 
outer monolayers of the vesicles in contact and maintaining intact 
the inner monolayers and the aqueous contents.81 For example, 
monoanionic phospholipids such as phosphatidylglicerol are 
transferred through the contacts, whereas zwitterionic 
phosphatidylcholine or dianionic phosphatidic acid are excluded, 
independently of the composition of the fatty acid chains. The non-
antibiotic derivative polymyxin B nonapeptide is not able to induce 
vesicle-vesicle contacts.82  Sublethal concentrations of PxB in 
growing E. coli induce a highly selective cellular stress, with 
transcription of the osmY gene without leakage of solutes and 
protons. 71,77,79 Since osmY expression is also induced by 
hyperosmotic stress, encoding a periplasmic protein that protects 
from cell membrane damage,83 the interpretation is that PxB forms 
functional contacts in the periplasmic space between the anionic 
phospholipid-containing outer surface of the cytoplasmic membrane 
and the inner surface of the outer membrane.84  The consequent loss 
of phospholipid compositional specificity caused by the PxB-
mediated exchange can be the origin of the osmotic imbalance that 
leads to bacteriostasis and cell death.14 An analysis of the 
transcriptome of A. baumannii exposed to colistin shows that this 
antibiotic alters the expression of a very large number of genes, 
many of them involved in the synthesis and transport of membrane 
components. This is consistent with the inner membrane-outer 
membrane lipid exchange mechanism of action with alteration of the 
normal membrane composition.85 
 
The structure of polymyxin in the IM-OM contacts has been 
characterized in lipid vesicles by fluorescence resonance energy 
transfer, using labelled derivatives of a synthetic PxB analog, sp-B.86 
Intermolecular FRET is consistent with self-association of the 
peptide, possibly forming dimers, when bound to anionic vesicles at 
concentrations that are relevant for formation of vesicle-vesicle 
contacts and lipid exchange. Atomic force microscopy of polymyxin 
bound to monolayers of E. coli lipid extract shows structures that are 
consistent with the formation of aggregates of several particles at 
the concentrations that induce contact formation.82   
 
A series of polymyxin analogs obtained by solid phase synthesis and 
including a disulfide bond gave additional information on the 
mechanism of action. For example, conservative analogs maintaining 
the main structural characteristics of polymyxin, namely 5 positive 
charged residues, a cyclic heptapeptide, a lineal tripeptide and the 
N-terminal acyl chain, are also active against Gram-negative bacteria 
and induce vesicle-vesicle contacts and a selective lipid exchange 
similar to polymyxin.87,88 However, substitution of Dab residues for 
Arg results in more lytic lipopeptides, with a different spectrum of 
activity that includes Gram-positive and Gram-negative bacteria.89,90 
Flow citometry of E. coli treated with one of the Arg-containig 
polymyxin analogs shows that depolarization and permeabilization 
take place roughly at the same time, and are consistent with a 
membrane-based mechanism of action.89,91 It has also been shown 
that polymyxin B and colistin are able to inhibit the vital respiratory 
enzyme type II NADH-quinone oxidoreductase (NDH-2) in the inner 





Figure 3: Representation of the putative mechanism of action of polymyxin 
on Gram-negative bacteria. (1) Displacement of Ca2+ and Mg2+ and binding to 
lipid A; (2) Self-promoted uptake to the periplasmic space and formation of 
OM-IM contacts and lipid exchange; (3) Inhibition of respiratory enzyme type 
II NADH-quinone oxidoreductase; (4) Entry into the cytoplasm and access 
intracellular targets. *Polymyxin B nonapeptide activity is limited to step (1). 
 
Interestingly, polymyxin B nonapeptide has no inhibitory activity, in 
agreement with its reported inability to cross the cell membrane. 
NADH-2 inhibition has also been identified in other compounds 
including phenothiazines, quinolinyl pyrimidines and quinolones, 
but in all cases the mode of action remain unclear and in the case 
of polymyxins is considered a secondary mechanism of action.93 
Polymyxin B and E can inhibit alternative membrane bound 
respiratory enzymes nicotinamide adenine dinucleotide 
dehydrogenase and malate:quinone oxidoreductase in 
Mycobacterioum smegmatis.36 
 
Some reports suggest that entry into the cytoplasm of the bacterial 
cell is not necessary for activity. For example, polymyxin B covalently 
attached to agarose beads has a good antimicrobial activity on E. coli 
and P. aeruginosa.94 It is proposed that perturbation of outer 
membrane structure by polymyxin-agarose indirectly affected the 
selective permeability of the inner membrane and inhibited 
respiration. However, the chemistry followed in this study did not 
provide selectivity to the anchoring point on the peptide, given that 
it includes multiple free amines, any of which could have reacted 
with the spacer arm bound to the agarose beads. A better example 
is a cysteinilated derivative of battacin, a close analog of polymyxin 
that retains its activity when covalently linked to a derivatized solid 
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prevent bacterial colonization and biofilm formation.95 The 
lipopeptide-coated surfaces caused significant damage to the cellular 
envelope of P. aeruginosa and E. coli upon contact and prevented 
surface biofilm colonization.  
 
It should be stressed that the mechanism of action of polymyxins on 
Gram-negative bacteria based on OM and IM interactions is well 
documented. However, other mechanisms involving intracellular 
targets can also play a role.15,96 Recently, entry of polymyxin into the 
cytoplasm of Gram-negative bacterial cells has been demonstrated 
by time-lapse laser scanning confocal microscopy using a dansylated 
polymyxin B that maintains the pharmacological properties of the 
natural antibiotic.97  In their work, the authors show that labelled 
polymyxin initially accumulated in the OM of K. pneumoniae, then it 
gradually penetrated the OM and accessed the IM, and only at high 
concentrations (5 x MIC) it became homogeneously distributed in the 
cytoplasm. The possibility of intracellular targets for polymyxins is 
not clear, but there are some studies that point in that direction.  For 
example, the generation of hydroxyl radical production by the 
Fenton reaction leading to the formation of hydroxyl radicals through 
the reduction of hydrogen peroxide by ferrous ion (Fe2+) has been 
observed in several Gram-negative species, including A. baumanii 
and E. coli,76,98 and K. pneumoniae.99 The production of reactive 
oxygen species (ROS) is concurrent with the rapid killing of these 
bacteria by both polymyxin B and colistin, probably by oxidative 
damage in the bacterial DNA, proteins and lipid.100 In support of this 
intracellular mechanism of action, a study by Pournaras et al.101  
shows that in a colistin-resistant isolate of A. baumanii there is a 
significant decrease in the expression of enzymes involved in 
oxidative stress response. An increase in expression of genes 
encoding superoxide dismutase enzymes after colistin treatment in 
A. baumanii also agrees with the idea of hydroxyl radicals being 
involved in colistin antibacterial activity.85 
6. Resistance to polymyxins  
The therapeutic rescue of polymyxins for their use in nosocomial 
infections has been followed by an emergence of acquired resistance 
among the most clinically relevant Gram-negative bacteria. 
Resistance to polymyxin is a complex subject that would require of 
another thorough review by itself. Hence, only a brief mention will 
be made here. Several recent reviews summarizing the mechanisms 
of resistance to polymyxins are also available. 53,102-105 As seen 
before, the first molecular target of polymyxins in the bacterial 
surface is the LPS of the outer membrane. Since electrostatic 
interactions are established with anionic phosphate groups in lipid A, 
modification of those with positively charged groups such as 
phosphoetanolamine or 4-amino-4-deoxy-L-arabinose provides a 
mechanism of protection from the interaction with polycationic 
polymyxin and thus, of resistance.106 Changes in lipid A may include 
deacylation, hydroxylation and palmitoylation. Other mechanisms of 
resistance include the utilization of efflux pumps and capsule 
formation. Resistance is mainly adaptive (reversible) and regulated 
by two-component systems (e. g.  PhoP/PhoQ and PmrA/PmrB) and 
can be triggered by environmental stimuli (low Mg2+ levels, sublethal 
concentrations of AMPs, for instance). Recently, resistance to colistin 
due to plasmid-mediated mcr-1 gene has also been described. MCR-
1 is a phosphoethanolamine transferase enzyme (it adds 
phosphoethanolamine to lipid A). Resistance to polymyxins is 
certainly an added challenge to the development of new antibiotics 
against pan-drug resistant Gram-negative bacteria.107 
7. Combination with other antibiotics 
The main interest of polymyxin combinations with other antibiotics 
lies in the treatment of infections caused by resistant and multidrug-
resistant bacteria whose proliferation is becoming a serious social 
and economic problem worldwide and account for growing global 
morbidity and mortality. Multidrug-resistant pathogens are 
considered those that are resistant to three or more antibiotic 
classes. The worst are the extensively drug-resistant (XDR) ones, 
particularly those Gram-negative pathogens that are non-susceptible 
to all but one or two antibiotic classes.108 In this situation, when even 
carbapenems, a major last-line class of antibiotics to treat bacterial 
infections, are not useful polymyxins have been rescued and become 
last-resort agents against XDR P. aeruginosa, K. pneumoniae and A. 
baumannii.  
 
The emergence of polymyxin-resistant strains and polymyxin 
heteroresistance (heterogeneity of response to antibiotics from 
bacterial cells within the same population) is questioning the utility 
of polymyxin monotherapies. Increasing the dose to maximize 
efficacy of the treatment is not viable since polymyxins are 
nephrotoxic and exhibit a narrow therapeutic index. An alternative 
option would be the administration of polymyxins in combination 
with other antibiotic agents or non-antibiotic compounds.109  The 
mechanism of action of polymyxins, that affects the integrity and 
enhance permeability of the outer membrane of Gram-negative 
bacteria, may help increase activity and accumulation110 within 
bacterial cell of other antibiotic classes. 
 
Several studies have explored the synergistic activity of polymyxins 
with other antimicrobial agents against Gram-negative bacteria, 
particularly P. aeruginosa, K. pneumoniae and A. baumannii. Synergy 
may be assessed in vitro by three methods:  time-kill studies, Etest 
and microdilution. The major interest of combinations is to show 
synergistic activity against resistant bacterial strains to at least one 
of the antibiotics, chiefly the one showing the highest MIC. One of 
the antibiotic classes most commonly used in combination with 
polymyxins is the carbapenem family. In a systematic review and 
meta-analysis, combination therapy following the time-kill method 
showed synergy rates of 44% (30 to 59%) for K. pneumoniae, 50% (30 
to 69%) for P. aeruginosa and 77% (64 to 87%) for A. baumannii. Of 
the carbapenems studied, doripenem showed high synergy rates for 
all three bacteria. Meropenem was more synergistic for A. baumannii 
and imipenem for P. aeruginosa. Etest and checkerboard assays 
generally yielded lower synergy rates than time-kill studies.111 
 
In addition to carbapenems, combinations of polymyxins with 
amikacin,112 ceftazidime,113,114 ciprofloxacin,114 fosfomycin,115-117 
gramicidin118,119 or rifampicin120 have been described to confer 
additive bactericidal activity against several P. aeruginosa strains in 
vitro. Regarding K. pneumoniae, efforts have been mostly devoted to 
K. pneumoniae carbapenemase (KPC) and metallo-β-lactamase 
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(MBL) producing strains.121 Synergistic activity has been observed in 
combinations with fosfomycin,115,122,123 vancomycin,124 
rifampicin,125,126 tygecicline,126  chloramphenicol,127  plazomycin,128 
and aztreonam.129 
 
The combination therapy of polymixin with rifampicin is one of the 
most tested options for the treatment of MDR and XDR Gram-
negative bacterial infections, and A. baumannii is no exception.130-134 
A lot of attention has also received the synergistic studies of 
polymyxins with glycopeptides (teicoplanin, vancomycin, 
telavancin).124,135-141 Partial synergy has been observed with 
azithromycin.142 Synergistic effectiveness of colistin with 
meropenem and sulbactam,143 minocycline144 and daptomycin, an 
anionic lipopeptide, has also been shown.145 Finally, the combination 
of lantibiotic nisin (normally used as a food preservative) with either 
colistin or polymyxin B yielded a pronounced synergistic effect in E. 
coli, K. pneumoniae, P. putida and P. aeruginosa.146 However, no 
additive effect was found with nisin in binary combination with 
penicillin, erythromycin or chloramphenicol. 
 
In summary, numerous studies have identified various polymyxin 
combinations presenting synergistic activity against sensitive and 
multi-drug resistant P. aeruginosa, K. pneumoniae and A. baumannii. 
Apparently, synergy was more evident in polymyxin-resistant strains, 
what augurs well for the combination therapy in front of polymyxin 
monotherapy. In addition, regrowth and emergence of resistance is 
consistently seen in polymyxin monotherapy. Given this situation, 
polymyxin combination therapy could reduce the possibility for 
selection of resistant subpopulations or the development of new 
resistance. Although most in vitro data endorse this view, clinical 
investigations of polymyxin combination therapy are in its infancy. 
So far, clinical data is apparently inconclusive in showing evident 
superiority of the cotherapy due to the small sample size studies, 
among other reasons.53,147-149 To overcome this issue, well-designed 
clinical tests are urgently needed to give a clear answer. In this 
regard, two large clinical trials comparing colistin monotherapy and 
colistin combined with meropenem are currently in progress both in 
Europe and the US.150  
8. Synergy with antifungals 
Polymyxins are known to have a poor fungicidal activity (MIC ≥ 8 
mg/L). However, the synergistic antifungal properties of polymyxin 
B were studied as early as 1972. Polymyxin was found to potentiate 
the activity of tetracycline in Candida albicans and Saccharomyces 
cerevisiae, even at low concentrations. Polymyxin B seemed to 
increase the permeability of the yeast cell membrane to tetracycline, 
which then inhibited protein synthesis and led to cell death.151  More 
recently, it has been demonstrated that the polymyxin B 
combination with fluconazole or itraconazole was active at low 
concentrations against Aspergillus fumigatus, Rhizopus oryzae, 
Candida albicans and non-albicans Candida species. The combination 
at clinically relevant low concentrations was particularly potent 
against Cryptococcus neoformans, including strains resistant to 
fluconazole.152 Polymyxin B has also been demonstrated to reduce 
the tissue fungal burden both in intravenous and inhalation models 
of murine cryptococcosis at a level comparable with that of 
fluconazole.38 
 
Synergistic antifungal activity against C. albicans has also been 
reported when polymyxin B was combined with amphotericin B, 
ketoconazole and miconazole.153,154 Similarly, colistin has also been 
found to act synergistically with amphotericin B against R. oryzae.155 
Colistin, both as a single agent or in combination with voriconazole, 
caspofungin and amphotericin B, has also shown in vitro antifungal 
activity against filamentous ascomycetes occurring in cystic fibrosis 
patients and may offer new therapeutic options, especially for 
multidrug-resistant Scedosporium prolificans.156 
 
In a recent study to assess the in vitro susceptibility of 25 clinical 
isolates of Fusarium to antifungal agents (amphotericin B, 
caspofungin, itraconazole and voriconazole) and antimicrobials 
(pentamidine, polymyxin B, tigecycline and tobramycin), the highest 
rates of synergism were observed when amphotericin B or 
voriconazole were combined with tobramycin (80 % and 76 %, 
respectively), polymyxin B (76 % and 64 %) and pentamidine (72 % 
and 68 %).157,158  
 
Finally, caspofungin and echinocandin antifungals in combination 
with colistin have also been found to act synergistically against 
fluconazole-resistant and susceptible C. albicans and C. glabrata 
isolates. However, authors also state that the correlation with in vivo 
benefits may not be straightforward.159-161  
9. Antibiofilm activity  
A biofilm is an organized microbial ecosystem that consist of one or 
more microbial species imbedded in a self-produced matrix of 
extracellular polymeric substances composed by proteins, 
polysaccharides and DNA. Biofilms can develop on human body 
tissues and surfaces of medical devices. Antibiotic treatments against 
biofilms usually require of high doses administered for long periods 
of time. Since current available antibiotics have been developed to 
target planktonic bacteria, they often fail to fight persistent 
infections associated with biofilms.162 
 
Polymyxins have been proven to be active against biofilms, both as a 
single agent or in combination with other antibiotics, particularly 
against A. baumannii and P. aeruginosa.163,164 However, neither 
colistin nor polymyxin B were found capable of preventing (p)ppGpp 
accumulation (alarmones guanosine 5’-diphosphate 3’-diphosphate, 
ppGpp, and guanosine 5’-triphosphate 3’-diphosphate, pppGpp) 
signaling nucleotides that regulate the stringent response in bacteria 
and are  known to play a role in biofilm formation.165 
 
Polymyxin was found to show an antibiofilm synergistic interaction 
with cyclic antimicrobial peptide gramicidin S toward 17 multidrug-
resistant P. aeruginosa and biofilms of P. aeruginosa strain PAO1. 
The concentration of polymyxin B required to inhibit biofilm 
formation by P. aeruginosa PAO1 was 8 μg/ml. Treatment in 
combination with gramicidin S required only  2 μg/ml (gramicidin S  
concentration got reduced from 32 μg/ml to 4 μg/ml ). The FIC 
(fractional inhibitory concentration) calculated from this decrease 
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was 0.375, which indicated a synergistic effect of this treatment.118 
Inhibition of biofilm formation by P. aeruginosa (PA-01 strain) has 
also been found between nisin lantibiotic and either colistin or 
polymyxin B. As a control, none of these antimicrobials inhibited 
biofilm formation when used individually.146  
 
Colistin and tobramycin, both alone or in combination exhibited 
bactericidal activity prior to biofilm attachment to endotracheal 
tubes, however no activity was observed once biofilm formed on 
such polyvinylchloride tubes.166 Polymyxin B proved to be 100% 
effective in vitro against a highly prevalent clone of multi-drug 
resistant A. baumannii, with a 92.9% of strains being biofilm 
producers (associated patient lethality of 28.2% in a Mexican Tertiary 
Care Hospital). However, no direct proof of polymyxin inhibiting 
biofilm formation in this clone was provided.167 
 
Recently, colistin entrapped in nanoparticles of different materials 
[poly (lactide-co-glycolide, chitosan, poly(vinyl alcohol] have been 
proven to eradicate pre-formed P. aeruginosa biofilms. 
Nanoparticles of colistin/poly(vinyl alcohol) and colistin/chitosan 
could penetrate inside the biofilms, release colistin in situ, thus 
increasing the effectiveness of the treatments.168,169 A synergistic or 
additive effect between colistin and levofloxacin has been reported 
in vitro and in Galleria mellonella model against colsitin-susceptible 
A. baumannii strains, although not against colistin-resistant ones.170 
10. Toxicity  
Toxicity of polymyxins has been reported since the beginning of its 
use. Toxicity is dose dependent and reversible once the treatment is 
discontinued. However, the exact molecular mechanism of toxicity is 
not well-understood.  
 
In 1947, Stansly and coworkers already described the 
sulfomethylation of polymyxin to reduce acute toxicity, according to 
previous reports describing the significance of transforming a 
cationic drug into an anionic one:  
 
R-NH2 + HCHO + NaHSO3    R-NH-CH2-SO3- Na+ + H2O 
 
They also observed that this sulfomethylated form of polymyxin was 
free of producing painful irritation when administered 
subcutaneously or intramuscularly.47 
 
The main adverse side effects of polymyxins are nephro- and 
neurotoxicity.171,172 The rate of colistin-associated neurological 
toxicity is approximately 7%. The major manifestation of neurotoxic 
side effects after parenteral colistimethate administration is 
paresthesia (“pin and needles sensation”).  Neuromuscular blockade 
can also occur during polymyxin therapy although no episodes have 
been reported in the literature in the last years. Ataxia, vertigo, 
confusion, dizziness, weakness, visual, speech disturbances, 
hallucinations and seizures are also possible during polymyxin 
therapy.  
The major toxicological problem of polymyxins is nephrotoxicity. 
Both polymyxin B and colistin/colistimethate are known to produce 
adverse side effects in kidney.171,172  Nephrotoxicity rates typically 
range between 10% and 60%. In the largest clinical study so far 
performed (258 patients) the rate of nephrotoxicity was found to be 
10%.173 In a series of recent studies carried out in cohorts of 71 and 
66 patients, acute kidney injury (AKI) rates associated to 
colistimethate administration were found to be 45-56% according to 
the Risk, Injury, Failure, Loss and End-stage (RIFLE) kidney disease 
criteria.174,175 In a study performed in Korea, AKI incidence was found 
to reach  54.6 % in a cohort of 119 patients.176 In another study 
involving 92 patients comparing a high-dose of colistimethate 
treatment (9 MIU, million IU, followed by a maintenance dose of 4.5 
MIU/12 h) versus the standard dose (6 MIU/day ), a higher cure rate 
in the high-dose group was found (63 vs. 41.3%, p = 0.04) with no 
higher risk of nephrotoxicity (32.2 versus 26%).177 In a smaller study 
involving 30 patients in Orlando (Florida, US), nephrotoxicity 
occurred in 3 out of 10 (33%) of patients. An interesting point of this 
study was that excessive colistimethate dosing was frequent (47%), 
often due to the higher body weight in obese patients (71%), and was 
associated with higher rates of nephrotoxicity (80% versus 30%). 
Overall, a close monitoring of the renal function in patients is 
mandatory to identify the optimal colistimethate dose from both 
efficacy and toxicity perspectives.178 The use of homogeneous 
criteria, such as the RIFLE one, when carrying out nephrotoxicity 
studies was also found to be necessary for the evaluation of acute 
kidney injury and allow for comparison of nephrotoxicity among 
reports. 
 
The use of potentially nephroprotective agents has been advocated 
to ameliorate adverse side effects of polymyxins (ascorbic acid, 
vitamin E, melatonin, lycopene, N-acetylcysteine). In rodent  in vivo 
models, some positive results showed that coadministration of 
antioxidants can protect against colistin-induced nephrotoxicity.179 
In the clinic, administration of intravenous ascorbic acid has been 
studied as a potentially useful component to prevent nephrotoxicity 
because of its antioxidant properties. However, evidence of a 
protective effect is not conclusive according to two clinical 
studies.180,181 
 
Since both polymyxins and colistimethate are nephrotoxic, a 
question rises regarding the relative toxicity of the free base in 
comparison with the methansulfonated derivative. Again, results are 
not conclusive. In a report by Oliveira in Brazil dealing with the 
treatment of infections (41 patients) caused by carbapenem-
resistant Acinetobacter spp,  both polymyxins gave equivalent results 
with regard to  efficacy and toxicity.177 In a systematic review and 
meta-analysis, unadjusted nephrotoxicity was more common in 
patients treated with colistin than with polymyin B, but according to 
the RIFLE criteria, there was no difference regarding risk, injury or 
failure between colistin and polymyxin B.183 Two other studies 
though, reported that nephrotoxicity rates were lower with 
polymyxin B than colistimethate.171,184,185 Also, polymyxin B seems to 
have some advantage over colistimethate regarding rapid target 
concentration attainment and antibacterial activity.186  
 
10.1. Mechanism of nephrotoxicity  
The mechanism of polymyxin-induced nephrotoxicity is not clear and 
numerous efforts are carried out to uncover it.187,188 The structure-
activity data on polymyxin analogs  seem to indicate that toxicity is 
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related to the amphipathic nature of the molecule, due to the 
presence of hydrophobic residues (fatty acid, amino acids 6 and 7) 
and particularly due to the presence of charged Dab side chains at 
physiological pH. Polymyxins accumulate within proximal tubular 
epithelial cells (PTEC) of the kidney via endocytosis at the multiligand 
receptor megalin. Megalin is highly expressed on the luminal surface 
of renal proximal tubules.  It is a negatively charged protein involved 
in the binding and endocytosis of polybasic molecules such as 
aprotinin, cytochrome c or aminoglycosides.189,190 The mechanism of 
nephrotoxicity of polymyxins has been proposed to be similar to that 
described for aminoglycosides.191,192 
 
Polymyxin-induced nephrotoxicity has been associated with acute 
tubular necrosis in kidneys and rise of creatinine levels in blood. 
Serum creatinine increments after parenteral administration of 
colistimethate are dose- and duration-dependent as proven in rats 
and humans. Phamacokinetic data indicate that polymyxins are 
extensively reabsorbed by active transport processes in the renal 
tubules after filtration at the glomerulus (from tubular urine back 
into blood).193 This major tubular reabsorption may induce an 
accumulation of the drug in the tubular cells and this could be, at 
least in part, a potential cause for nephrotoxicity. Accumulation of 
polymyxin induces apoptosis in kidney tubular cells194 and may be 
the result of mitochondrial damage and/or release of reactive 
oxygen species.187 The urinary recovery of polymyxin B and colistin is 
less than 1%, as proven in humans and rats, respectively. Thus, it is 
evident that nonrenal elimination is the predominant clearance 
pathway for both polymyxins. However, the urinary recovery of 
sodium colistimethate can be higher than 60% (as seen in assays in 
rats, dogs and humans). The explanation may come from the 
different ionic nature of both polymyxins (polycations) and 
colistimethate (a polyanion). Urinary concentrations of colistin after 
administration of colistimethate can be relatively high as a result of 
hydrolysis within the urinary tract from colistimethate that is 
extensively renally excreted (and not reabsorbed). Partially 
sulphomethylated derivatives of colistin are also excreted before the 
full hydrolysis and are not reabsorbed.195-197 
 
Recently, a detailed study by Mass Spectrometry Imaging (MSI) 
helped to reveal the distribution of polymyxin B1, colistin, and the 
less nephrotoxic truncated derivative, polymyxin B nonapeptide 
within rat kidney.198 The bioanalysis showed that polymyxin B1 and 
colistin preferentially accumulated in the renal cortical region while 
polymyxin B nonapeptide, a less nephrotoxic compound, was more  
uniformily distributed throughout the kidney. Ratios of relative 
proportions of kidney cortex:medulla at seven days were 5.8 to 1 
 
Figure  4: Polymyxin B1 metabolites found in renal cortex in addition 
to polymyxin B1 itself. Metabolites were identified by LC/MS/MS 
(Liquid Chromatography, Mass Spectrometry) according to Nilsson 
and coworkers (M5, unknown structure). Arrows indicate peptide 
bonds metabolized by hydrolysis.198 
 
for colistin and 25.4  to 1 for polymyxin B.  For polymyxin 
nonapeptide, the ratio was 2.9 to 1. These results correlate with 
recent immunohistochemical and correlative microscopy studies, 
which also demonstrated that polymyxins accumulate within renal 
tubular cells of the renal cortex.199-202 In addition, metabolites that 
accumulate with a similar distribution as the parent polimixins have 
also been identified by high resolution MS (Figure 4). 
 
Both tissue homogenates and urine samples were analyzed. Ten 
polymyxin metabolites were identified within the tissue 
homogenates, six of which were also found in the urine sample. No 
quantification of the relative abundances of the different 
metabolites was provided, though. Nevertheless, it is interesting to 
see that both non-metabolized polymyxin and colistin accumulate in 
renal cortex and their image intensity increases during the seven 
days of the experiment. Some metabolites imply minor modification 
(oxidation, demethylation) of the parent polymyxin, with small 
reductions of molecular weight. Other metabolites comprise the 
sequential hydrolysis of the linear lipotripeptide moiety without 
affecting the cyclic heptapeptide structure. Regarding colistin 
metabolization, similar byproducts were found. However, one of the 
metabolites detected involved the partial hydrolysis of cyclic 
structure in this case (colistin metabolite M5, not shown).198 
Altogether, this study suggests that in spite of the fact that the 
majority of kidney’s drug metabolizing and detoxification enzymes 
are located in the proximal tubule,203 a significant proportion of 
polymyxin molecules remain non-metabolized in renal cortex, what 
seems to indicate that polymyxins are apparently quite stable 
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molecules. In fact, polymyxins accumulate and are reabsorbed in 
proximal tubules, as we have seen before, and are mainly eliminated 
by non-renal clearance mechanisms. 
 
10.2. Biomarkers of nephrotoxicity 
Monitoring of drug-induced kidney injuries is an important issue 
during drug development. Hence, validation of kidney injury 
biomarkers is necessary for the clinical application and regulatory 
issues. In acute kidney injury according to the RIFLE criteria, the 
determination of plasma and serum creatinine levels remains as a 
standard of diagnosis. Creatinine is a useful biomarker of kidney 
damage in patients suffering of stable chronic renal diseases, but it is 
not convenient in the case of acute kidney disease. More than half of 
kidney function is lost before AKI is detected by an increase of serum 
creatinine levels as they are detected 24-48 hours following the 
initial kidney insult. Colistimethate treatments are often 
discontinued when minor increments in creatinine levels are 
detected because of the risk of negative outcomes, even if patients 
are responding to the antibiotic therapy. Hence, there is a need of 
novel kidney injury urinary biomarkers that can detect AKI much 
earlier in order to avoid such decision time lag. Several biomarkers 
are a subject of study to allow for an early and site-specific prediction 
of AKI. These indicators can detect initial kidney injury in 4-6 hours. 
Biomarkers for tubular damage include Kidney Injury Molecule-1 
(KIM-1), α–Glutathione S-Transferase (α–GST), π-Glutathione S-
Transferase (π–GST) and NGAL (Neutrophil Gelatinase Associated 
Lipocalin).197,204,205 
 
KIM-1 is a type I trans-membrane structural glycoprotein present on 
epithelial cells of the renal proximal tubule. KIM-1 is undetectable in 
healthy tissue but highly upregulated on the apical surface of 
proximal tubule epithelial cells after renal injury, i. e.  in response to 
toxic and ischemic injury. The ectodomain shedding of KIM-1 into 
urine makes it an early and specific biomarker for AKI. 
 
α–GST and π–GST are small cytosolic isoenzymes and members of 
the GST superfamily. They are primarily involved in cellular 
detoxification metabolic reactions since they catalyze the 
conjugation of the reduced form of glutathione (L-γ-glutamyl-L-
cysteinyl-glycine) to xenobiotic substrates. They can form up to 2% 
of the total cytosolic soluble protein content in the cytoplasm. α-GST 
and π-GST are immediately released into the urine upon lysis of 
epithelial cells of the proximal and distal tubule, respectively, 
converting them in a rapid and sensitive biomarker of AKI. 
Simultaneous detection of both GST proteins permits discrimination 
between proximal and distal tubular damage. 
 
NGAL is small extracellular glycoprotein that is characterized by the 
ability to bind small hydrophobic molecules. NGAL is rapidly 
upregulated and thus, an early biomarker for the detection of AKI 
onset in various clinical settings including cardiothoracic surgery, 
intensive care-unit, and nephropathy. 
 
In a study carried out in rats, KIM-1 and α-GST proved to be the most 
sensitive biomarkers to polymyxin-induced AKI, outperforming 
current nephrotoxicity standards of care (creatinine and blood urea 
nitrogen) proving that they are not suitable for detecting 
nephrotoxicity of polymyxin in this in vivo model.197 NGAL and π-GST 
also proved to be useful indicators according to same study. In 
another in vivo study performed simultaneously in rat, dog and 
monkey, similar results were obtained for the rat model, with NGAL 
and KIM-1 capable of detecting AKI (GST biomarkers were not 
tested). However, in the dog and monkey models, both standard 
(creatinine and blood urea nitrogen) and more recent biomarkers 
(NGAL and KIM-1) showed a rapid onset of response.204 In this case, 
though, the added value of urinary NGAL and urinary KIM-1 
biomarkers was their selectivity in the localization of the injury within 
the kidney (proximal and/or distal tubules versus the glomerulus) 
and can help to discriminate the development of acute kidney injury 
onset.205 
11. Design and development of new polymyxins 
The growing incidence of bacterial resistance in hospitals and 
healthcare settings, the dry pipeline of new antibiotics, and the fact 
that polymyxin B and colistin have become last line antibiotics to 
treat highly drug resistant infections in spite of their toxicity liabilities 
has led to several worldwide research initiatives in recent years to 
design and develop new polymyxin analogs. The goals are to improve 
activity, reduce adverse side effects, mostly nephrotoxicity, and 
understand the relationship of activity and toxicity with the chemical 
structure of polymyxins. 
 
First efforts aiming at these objectives started in the 1970s. However, 
the difficulty in access to reliable peptide synthesis schemes for the 
preparation of cyclic peptide analogs and the limited knowledge of 
polymyxin pharmacology reduced the structural and chemical space 
of explored analogs.14,15,206-210 Thus, compounds were generated by 
acylation or alkylation of Dab residues, or substitution of the N-
terminal fatty acid tail sometimes following semisynthetic 
approaches from truncated versions of polymyxin such as the 
nonapeptide (PBNP). The view that emerges from this initial 
background is that amphipathicity in polymyxins is crucial for activity, 
which includes the charged Dab residues on the one hand and the 
fatty acid tail and the conserved hydrophobic residues in position 6 
and 7 on the other.  
 
Another trend that can be observed relates to the fact that in 
general, activity in polymyxins runs parallel to toxicity, i. e. more 
active compounds tend to be more toxic to mammalian cells. Hence, 
new approaches should be sought to break this activity/toxicity 
correlation in polymyxins. In the last decade or so, several academic 
and private teams worldwide got involved in the design and 
development of novel polymyxin analogs to overcome the 
drawbacks posed by the natural compounds, that is to say, improve 
safety and efficacy.    
 
11.1  Synthetic preparation of polymyxin analogs 
Preparation of novel polymyxin analogs is performed following two 
main approaches: semisynthesis and total chemical synthesis. The 
first strategy, semisynthesis, starts from the natural polymyxin 
product, usually obtained by fermentation procedures.211 Although 
this is a readily  accessible and affordable approach, it is  curtailed by 
the few possibilities of modifying the cyclic heptapeptide core and 
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normally analogs are reduced to truncation or substitutions in the 
linear lipotripeptide moiety by enzymatic treatment. Enzymatic 
hydrolysis of the linear segment of polymyxin gives access to 
truncated analogs of polymyxin, such as the deacylated decapeptide 
by means of a polymyxin acylase treatment or to the well-known 
PBNP by treatment with papain or plant proteinase ficin.202-203 
Treatment with bromelain enzyme yields polymyxin octapeptide 
(polymyxin 3-10) while hydrolysis with Nagarse furnishes the 
heptapeptide (polymyxin 4-10, heptacycle devoid of the N-teminal 
lipotripeptide).210-211 Further elaboration of the polymyxin fragments 
is possible by means of several selective protection schemes (Boc, 
tert-butoxycarbonyl, Fmoc, 9-fluorenylmethoxycarbonyl) and 
strategies as discussed below for each particular case.  
 
Total chemical synthesis of polymyxins generally involves the solid-
phase methodology using different polymeric supports and 
protecting groups such as Fmoc, Boc, tBu (tert-butyl), Dde (1-(4,4-
dimethyl-2,6-dioxocyclohex-1-ylidene)ethyl), Z (benzyloxycarbonyl) 
or Bzl (benzyl). Below, efforts by private companies and universities 
devoted to the design and development of polymixins are 
summarized. 
 
11.2 CB-182,804 analog 
This was the first synthetic polymyxin B derivative that entered a 
clinical trial. Originally developed by BioSource Pharm and licensed 
to Cubist Pharmaceuticals (now part of Merck), it had its N-terminal 
fatty acyl moiety substituted by an aromatic urea, a 2-chloro-
phenylaminocarbonyl unit (Figure 5). 
 
The analog CB-182,804 was prepared by semisynthesis from natural 
polymixin obtained by fermentation. Side chain Dab amino groups 
were protected with the Sulfmoc group (HSO3-Fmoc) by reaction 
with 9-(2-sulfo)fluorenylmethoxycarbonyl-N-hydroxysuccinimide. 
The resulting penta-Sulfmoc protected polymyxin was treated with a 
deacylase enzyme (from Actinoplanes ulahensis NRRL 12052) to 
remove the fatty acid tail and the resulting N-terminal free amino 
group was reacted with 2-chlorophenylisocyanate to yield the 
o-chlorophenyl urea. Finally, the Sulfmoc protecting groups were 
removed with piperidine in methanol to obtain the expected 
polymyxin derivative.212  
 
In vitro activity of CB-182,804 showed MIC90 (minimal concentration 
to inhibit growth of 90% of bacteria strains) values for E. coli, K. 
pneumoniae and P. aeruginosa around 2-4 μg.mL-1, similar or slightly 
higher (less potent) than polymyxin B/colistin.212,213  It was also 
demonstrated to be substantially less toxic in vitro since an EC50 of 
more than 1000 μg.mL-1 was obtained in rat kidney proximal tubule 
cell cultures whereas  EC50 was  318 μg.mL-1 for polymyxin B.  
 
CB-182,804 was tested in eight rodent infection models for efficacy 
against five Gram-negative pathogens. The efficacy of CB-182,804, 
for instance, compared favorably to that of polymyxin B, colistin, 
ciprofloxacin, or imipenem-cilastatin in an in vivo model of P. 
aeruginosa lung infection in neutropenic mice. 
 
Figure 5: Chemical structure of analog CB-182,804  
 
 
Similarly, in an A. baumannii thigh infection model in neutropenic 
mice, it also compared favourably to polymyxin B, colistin or 
imipenem-cilastatin. Pharmacokinetic features showed differences 
with respect to polymyxin B, particularly, decreased serum protein 
binding, and increased plasma clearance and volume of distribution.  
 
Finally, CB-182,804 was tested in cynomolgus monkeys for renal 
toxicity in a seven-day study. CB-182,804 showed lower 
nephrotoxicity than polymyxin B. Histopathological changes were 
characterized by minimal to mild degeneration/necrosis (6.6 
mg/Kg/day dose).212 
 
There was a mild associated increase in blood urea nitrogen and 
serum creatinine at higher dose with an increase in severity of 
histological kidney changes (9.9 mg/Kg/day). However, these kidney  
findings were markedly less than the ones found for polymyxin B 
when administered at equivalent antimicrobial doses. CB-182,804 
progressed into a phase I clinical trial (safety and pharmacokinetics 
in healthy humans) in February 2009 but in September 2010, it was 
discontinued. Results have apparently not been published. 
 
 
11.3 Pfizer 5x analog 
A series of biaryl and heterobiaryl N-terminal substituted derivatives 
of polymyxin have been described by Magee and coworkers in 
Pfizer.214 Position 3 that usually contains a Dab amino acid in natural 
polymyxins was substituted by Dap (L-1,3-diaminopropanoic acid) in 
the analogs (Figure 6). This substitution conferred a higher 
antimicrobial activity and reduced cytotoxicity in human PTEC cells. 
Compounds were prepared by solid phase chemical synthesis on a 
2-chlorotrityl chloride resin following a Fmoc/tBu/Z/Dde scheme of 
protection and macrocyclization in solution at high dilution 
conditions (0.002M). The heterobiaryl moiety was introduced by 
acylation reaction of 6-oxo-1-phenyl-1,6-dihydropyridine-3-
carboxylic acid. Antimicrobial potency of 5x was similar to the one of 
polymyxin B, as judged by MIC50 and MIC90 (equal or half the value) 
against susceptible and resistant strains of P. aeruginosa, A. 
baumannii, E. coli and K. pneumoniae.  
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Figure 6: Chemical structure of Pfixer 5x analog  
 
 
Compound 5x showed improved cytotoxicity in human PTEC cell line 
(TC50 >100 μM) in comparison with polymyxin B (TC50 >22 μM). A 
extensive comparative in vivo safety study in rat and dog models was 
performed. In a seven-day exploratory toxicological study, 5x 
showed no incidence of necrotic kidney lesions at 4 mg/Kg/day dose 
while polymyxin B yielded necrotic kidney lesions in every animal 
although graded to be minimal. At twofold dose (8 mg/Kg/day), 5x 
produced no kidney lesions whereas polymyxin B was not even 
tolerated. However, the dog model proved to be more sensitive to 
this seven-day exploratory toxicological study. Although at a low 
dose of 5 mg/Kg/day was well tolerated, minimal nephrotoxicity 
signs were already observed in all eight animals tested. At higher 
doses (11 and 20 mg/Kg/day) histopathology revealed moderate to 
marked nephrotoxicity signs. Although the severity of renal lesions 
was higher for polymyxin B, the authors conclude that there was no 
significant safety margin in dog and further preclinical development 
was not pursued. This result also demonstrates that the broad in vitro 
difference in cytotoxicity observed in the PTEC assay in favor of 5x 
versus polymyxin B did not correlate with the in vivo safety test in 
dog. Thus, authors conclude that further work needed to be carried 
out to develop in vitro assays that are able to predict nephrotoxicity 
in preclinical models, particularly non-rodent ones. 214 
 
11.4 Monash FADDI analogs 
The Monash Institute of Pharmaceutical Sciences has also addressed 
the design of new polymyxin analogs focusing mainly in the 
hydrophobic domains of the molecule, residues 6 and 7 in the 
heptapeptide cycle and the fatty acid tail.  Compounds were 
prepared by total chemical synthesis on solid phase. A 
Fmoc/tBu/Dde scheme of protection on a trityl resin  was used. 
Macrocyclization took place in solution at high dilution conditions.  
Design of the analogs incorporated new hydrophobic moieties such 
as octylglycine (L-2-aminodecanoic acid) and biphenylalanine that 
resulted in a substantial improvement of in vitro potency against 
polymyxin resistant isolates.215  
 
FADDI-002  and FADDI-003 (Figure 7) yielded MIC of 2-4 μg.mL-1 
against polymyxin-resistant strains of P. aeruginosa (32 to >32 
μg.mL-1  for polymyxin B) and A. baumannii (2-16 μg.mL-1 in front of 
8-128 μg.mL-1 for polymyxin B). Against polymyxin sensitive strains, 
though, FADDI analogs were slightly less potent compared to 
polymyxin and colistin (MIC 1-4 μg.mL-1 compared to 0.5-2 μg.mL-1). 
Activity against Gram-positive bacteria was also reported and 
resistant strains of Staphylococcus aureus and Enterococcus faecium 








In an in vivo mouse lung infection model, FADDI-002 demonstrated 
better efficacy than colistin against a polymyxin resistant clinical 
isolate of P. aeruginosa.  Regarding safety and tolerability, no 
adverse effects were detected when a bolus dose of FADDI-002 was 
administered in rats (intravenous, 0.75 mg/kg) and mice 
(subcutaneous, 40 mg/kg). These in vivo preliminary results 
suggested that the FADDI series had at least a comparable tolerability 
to polymyxin in rodents. Further exploration led to substitution of 
position 7 with a threonine (analog FADDI-100), reminiscent of 
polymyxin M. FADDI-100 rendered a reduction of nephrotoxicity but 
when tested for potency in a collection of 250 P. aeruginosa isolates 
from Rempex-The Medicines Company, a MIC90 of 32 μg.mL-1  was 
obtained.216 Finally, FADDI-287, a polymyxin E3 analog with position 
7 substituted by acid L-2-aminobutanoic (Abu) and Dap in position 3 
(like analog 5x reviewed before), provided high potency (MIC90=1 
μg.mL-1  in the same collection of P. aeruginosa isolates; MIC90=0.5 
μg.mL-1 against 210 A. baumannii isolates). In vivo kidney 
histopathology in mouse model (dose at 12 mg base/Kg, 
subcutaneously, every 2h x 6) showed much lower level of 
nephrotoxicity (mild acute tubular damage with tubular dilation) 
than polymyxin B (severe acute tubular damage and cortical 
necrosis). Efficacy test in mice were also encouraging.216 
 
11.5 Queensland analogs 
Cooper’s group at the University of Queensland has been involved in 
the design and preparation of polymyxins and octapeptins. In an 
article by Gallardo-Godoy and coworkers, they performed a 
systematic activity-cytotoxicity study involving the preparation of 32 
analogs probing eight of the amino acid positions in polymyxin 
(Figure 8).217 Compounds were prepared by solid-phase chemical 
synthesis following a Fmoc/tBu/allyl scheme of protection on DHP 
polystyrene resin (3,4-Dihydro-2H-pyran-2-yl-methoxymethyl 
polystyrene) with side chain anchoring of the C-terminal threonine. 
Selective Dab modification was also achieved with the use of ivDde 
(1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)isovaleryl) protecting 
group when necessary. 
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Figure 8: Chemical structure of University of Queensland analogs (Aa 
corresponds to the side chain of the indicated amino acid). 
 
MIC results confirmed that more lipophilic side chains at positions 
6/7 improved activity against polymyxin-resistant strains but 
increased cytotoxicity in mammalian cells. Substitution of the Dab 
residues rendered different behavior depending on the position. 
Dab-5 and Dab-9 could not be replaced without severely affecting 
potency, while Dab-8, Dab-3 (substituted by Gly, Thr, D-Dab or D-Ser, 
the last two reminiscent of polymyxins A, D, S or P) and Dab-1 
tolerated some substitutions. 
 
Another interesting result of the study was the nephrotoxicity 
predictive potential of in vitro cytotoxicity tests, an issue that was 
also discussed at Pfizer's work with analog 5x.214 Polymyxin B and 
colistin cytotoxicity were tested using cell lines HepG2 (hepatocyte 
carcinoma cells) and HEK293 (embryonic kidney cells). Results 
showed an apparent lack of toxicity (CC50 >300 μM) whereas in 
primary renal cell assay measuring LDH (Lactate Dehydrogenase) and 
GGT (Gamma Glutamyl Transferase) release, toxicity was clearly 
evidenced (CC50 of 23-177 μg/mL).217 An opposite behavior was 
observed with analog 14 of the series that yielded some toxicity 
readout in cell lines (287-296 μM) while in primary cultures gave a 
CC50 of >128 μg/mL.  
 
11.6 Northern Antibiotics analogs 
The team of Vaara at Northern Antibiotics in Helsinki has described a 
series of polymyxin analogs carrying only the three Dab residues. 
Compounds are obtained by substituting one or two of the Dab 
residues by D-Thr, D-Ser or Abu (2-aminobutanoic acid) amino acids, 
shortening the length of the linear tripeptide moiety of natural 
polymyxin, or both. The reason for this design lies in the fact that 
reducing the cationic character by eliminating some of positive 
charges in the molecule may also lead to a reduction in 
nephrotoxicity (Figure 9). Compounds of this family have direct 
antimicrobial activity (NAB739 NAB815) or sensitizing activity with 
other antibiotics (NAB741 and NAB7061). Analogs were synthesized 
following conventional solid phase chemical methods using a 
Fmoc/Bzl/Boc strategy of protection. Cyclization was carried out in 
solution.16 Analog NAB739 is based on polymyxin B but the N-
terminal lipotripeptide has been substituted by an octanoyl-Thr-DSer 
segment. NAB739 exhibited good antimicrobial potency against 
Enterobacteriaceae comparable to the one of polymyxin B.  
 
 
Figure 9: Chemical structure of Northern Antibiotics analogs (Aa 
corresponds to the side chain of the indicated amino acid).  
 
Against E. coli, a concentration of 1 µg/mL of NAB739 inhibited 
growth in 74.5% of the strains while polymyxin B inhibited 84.3% of 
the strains in the same conditions. Against K. pneumoniae, the values 
of MIC90 for NAB739 and polymyxin B were 2 and 1 µg/mL, 
respectively. However, NAB739 was not so active against A. 
baumannii (MIC90 was 8 µg/mL, four-fold that of polymyxin B), P. 
aeruginosa (MIC90 was 16 µg/mL, eight-fold) and polymyxin-resistant 
strains.218,219 In addition to antibacterial activity,  NAB739 displayed  
sensitizing activity at subinhibitory concentrations, facilitating the 
penetration of other antibiotics into bacterial cells. Against A. 
baumannii  and at a concentration of 0.5 μg/mL, NAB739 had 
synergistic activity and reduced the MIC of rifampicin (from 4–12 to 
0.05–0.1 μg/mL), clarithromycin (from 6–8 to 0.5 μg/mL) and 
vancomycin (from 256 to 3 μg/mL).220-222 Cytotoxicity of NAB739 
proved to be 26-fold less toxic than polymyxin B in HK-2 (human renal 
proximal tubular) cells with a CC50 of 337 and 13 µg/mL, respectively 
(colistin's was 45 µg/mL). In permeabilized (electroporated) LLC-PK1 
(porcine renal proximal tubular) cells, polymyxin B induced necrosis 
at 0.016 mM (ca 20 µg/mL), some 8-fold lower than that for NAB739. 
NAB739 was found to be effective in treating E. coli peritoneal 
infection in mice (dosed at 1 mg/Kg twice).223 Recently a new analog 
NAB815 has been reported, presenting MIC90 values 2-fold less active 
against E. coli and K. pneumoniae and 2-fold more active against A. 
baumannii than NAB739 (both overall less active than polymyxin B). 
However, in vivo tests have shown that both NAB815 and NAB739 
are better tolerated than polymyxin B in cynomolgus monkeys. In 
fact, a very significant portion of the dose of NAB815 and NAB739 is 
excreted into urine within 8 h after an intravenous infusion.224 
Further studies will reveal their potential use in the clinic. 
 
Sensitizers, although sometimes devoid of intrinsic antimicrobial 
activity, retain the ability to permeabilize the outer membrane of 
Gram-negative bacteria. Polymyxin nonapeptide, a truncated version 
of polymyxin, is a long time kown paradigm example: it is able to 
increase susceptibility of E. coli and other Enterobacteriacea to some 
antibiotics, particularly lipophilic and amphiphilic ones, up to 100-
fold times, at even low concentrations (1-3 μg/mL). In addition, since 
it lacks the N-terminal fatty tail, it is less nephrotoxic.221 NAB741 and 
NAB7061 are analogs of polymyxin B and NAB739, but their N-
terminal lipopeptide segments are acetyl-Thr-DSer and octanoyl-Thr-
Abu, respectively, thus carrying only three positive charges. Both 
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compounds are devoid of direct antibacterial activity but are able to 
potentiate the 10- to 2000-fold the activity of hydrophobic 
antibiotics (e.g. macrolides, rifampicin) or large amphiphilic 
antibiotics (e.g. vancomycin) against Enterobacteriaceae and A. 
baumannii. 
 
The synergistic activity of NAB7061 has been also proven in vivo, in a 
mice model of E. coli peritoneal infection. Similarly,  the combination 
of NAB7061 (dose 5 mg/kg) and erythromycin (10 mg/kg) was also 
effective.220 NAB741 has recently proceeded into preclinical studies, 
renamed as SPR741 due to an in-license agreement with Spero 
Therapeutics.225 SPR741 showed low nephrotoxicity in vivo in 
cynomolgus monkey and rat models. Only minimal tubular 
degeneration was observed at a dose of 60 mg/Kg.day in monkey.226 
SPR741 will enter phase I clinical trial (double-blind, placebo-
controlled, ascending dose, multi-cohort trial evaluating safety, 
tolerability and pharmacokinetics) as a potentiator compound.227 
 
11.7 Cantab analogs 
Cantab Anti-Infectives has generated a series of polymyxin analogs 
focusing on the modification of the N-terminal fragment (Figure 10). 
Actually, the preparation of compounds was performed from either 
polymyxin nonapeptide (tetra-Boc protected) obtained from natural 
polymyxin B by enzymatic treatment with papain or from polymyxin 
heptapeptide obtained from the penta-Boc protected polymyxin by 
treatment with savinase in acetonitrile-water mixture.228-231 
Carboxylic acids to be coupled to the corresponding peptides were 
obtained from commercial sources or prepared in house. Some 
analogs (example 50 in Brown’s patent)229 were also prepared by 
conventional Fmoc solid-phase chemistry and cyclized in solution. 
Amino acyl moieties in some analogs had the aminoalkyl side chain 
of natural Dab 1 embedded in piperazine (analog CA824) or 
piperidine (CA 900) rings.  MIC90 of the three selected analogs CA900, 
CA824 and CA1049 gave similar or slightly better values than 
polymyxin B against typical Gram-negatives such as E. coli (0.125 vs 
0.25 μg/mL for polymyxin B), A. baumannii (0.25-2 vs 1 μg/mL), P. 
aeruginosa (1 vs 8 μg/mL) and K. pneumoniae (0.25 vs 0.5 μg/mL). 
CA900 gave particularly good activity against A. baumannii, with a 
MIC90 of 0.125 μg/mL compared to the one of polymyxin (1 μg/mL). 
All three analogs were less cytotoxic in HK-2 cell cultures (TC50 of 64, 
148 and 167 μg/mL for CA 1049, 824 and 900, respectively) than 
polymyxin (TC50 of 15 μg/mL).232 
 
In vivo efficacy was carried out with CA824 analog. In neutropenic 
mouse lung infection models, the antibacterial activity of CA824 
proved to be superior to polymyxin B against A. baumannii NCTC 
13301 and P. aeruginosa ATCC 27853 while in a mouse thigh 
infection model, the antibacterial activity of CA824 against the same 
A. baumannii strain was comparable.233 In January 2017,  Spero 
Therapeutics acquired the assets developed by Cantab Anti-
Infectives to the owner Pro Bono Bio Ltd to bring the program 
through pre-clinical and clinical stages of development.234 
 
11.8 Scaffold modified polymyxins 
Throughout this review we have seen that antimicrobial potency in 
polymyxins tends to correlate with toxicity. Both antimicrobial 
activity and toxicity side effects in mammalian cells seem to be 
associated to the amphipathic nature of the molecule (hydrophobic 
and polycationic). 
 
Figure 10: Chemical structures of Cantab analogs 
 
 
A reasonable approach to break this parallel activity could be the 
modification of the backbone of the structure, a fact that is also 
compatible with the substitution of the amino acids of the sequence 
or the fatty acid to modify the periphery of the molecule. This idea 
would link to what it is known as soft drug design, which essentially 
means integrating metabolism considerations into the drug design 
process.235 With this purpose, different chemical units or bonds are 
introduced into the scaffold to help metabolism to deactivate and 
detoxify the molecule once it has exerted its desired antimicrobial 
activity. 
 
In section 10.1., we have seen that polymyxin B and colistin are quite 
stable molecules. They seem not to be fully metabolized or detoxified 
in the kidney and accumulate in the renal cortex despite the fact that 
the majority of kidney’s drug metabolizing and detoxification 
enzymes are located in the proximal tubule (see below). For instance, 
B- esterases, peptidases and oxidorreductases are localized relatively 
in high amounts in proximal tubule kidney cells. 
 
Two examples of polymyxin analogs have been recently described in 
the literature  that contain modifications in the peptide backbone 
designed to aid in the metabolization and prevent accumulation in 
kidneys, and hence, potentially reduce toxicity: ester-containing (i. e. 
depsipeptide) analogs of polymyxin (MicuRx and Barcelona)236,237 
and disulfide cyclized analogs (Barcelona).91,237  
 
 
11.9 MicuRx analogs 
MicuRx has described analogs that incorporate ester, carbamate and 
phosphate/phosphonate/phosphoramide type of bonds within the 
N-terminal part of polymyxin (Figure 11).236 The introduction of 
esters within polymyxin has been described before.229,238  
Compounds were prepared by semisynthesis from polymyxin 
nonapeptide and adding conveniently protected Fmoc/tBu amino 
acids, such as Boc-protected homoisoserine (L-2-hydroxy-4- 
aminobutanoic acid), Fmoc-Dab(Boc)-OH or other acids,  by means 
of standard coupling techniques and reagents. 
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Figure 11: Chemical structure of MicuRx analogs and the hydrolysis 
products rendered by esterases 
 
 
Some fifty polymyxin analogs were prepared. Analogs 12 and 18 
offered antibacterial activity comparable to polymyxin B and had an 
ester bond embedded in the fatty acid moiety. They both yielded MIC 
of 2 μg/mL against E. coli (vs 2-4 μg/mL for polymyxin B), 2 and 4 
μg/mL, respectively against P. aeruginosa (vs 2-4  μg/mL) and 2 and 
4 μg/mL, respectively against K. pneumoniae (vs 2-4  μg/mL). 
Cytotoxicity of both analogs in human HK-2 cells was lower (IC50 > 
200  μM) than that of polymyxin B (IC50 = 82  μM).236 
 
In vivo efficacy of analogs 12 and 18 in E. coli septicemia, P. 
aeruginosa thigh infection, and P. aeruginosa lung infection mouse 
models proved to be comparable to the efficacy results obtained for 
polymyxin B. A reduction of in vivo nephrotoxicity in rat model was 
observed for both in comparison with polymyxin B according to the 
low levels of urine biomarker NGAL (see section 11 before). Finally, 
stability in human plasma demonstrated that 66-67% of the original 
ester compounds 12 and 18 remained non-hydrolized after 1 h (at 4 
h, 31 % and 18%).236 
 
11.10 Barcelona analogs 
The University of Barcelona has described analogs of polymyxin 
where the amide bond between the γ–amino group of Dab4 and the 
C-terminal carboxy group of Thr10 has been replaced with a disulfide 
bond (Figure 12).91 This replacement is isosteric and implies the 
substituition of those amino acids with cysteines with an appropriate 
configuration of the α-carbon (L-cysteine in position 4 and D-cysteine 
in 10). The disulfide link may provide polymyxin analogs with 
sufficient stability to reach the infectious target in vivo. However, in 
an eventual accumulation and uptake by renal cells, the disulfide 
bond may be broken thus opening up the cyclic heptapeptide due to 
the reducing intracellular environment (reduced glutathione and 
oxidorreductases) that could facilitate peptide proteolysis and 
potentially lower renal toxicity. In this respect, detoxification of 
xenobiotics in kidney is carried out by metabolizing enzymes that are 
involved, for instance, in the conjugation of glutathione, glucuronic 
acid, or sulfate. These enzymes, including cytochrome P-450, are 








In particular, proximal tubular cells exhibit a high activity in 
glutathione redox cycle enzymes, such as glutathione disulfide 
reductase, GSH peroxidases, and GSH S-transferase. The intracellular 
concentration of glutathione in proximal tubular cells is around 2-5 
mM whereas in the lumen is at least two orders of magnitude lower. 
In blood, GSH concentration is around 20 µM.203,239,240 
 
Furthermore, in an in vivo study in rat dealing with the metabolism 
and retention of octreotide (a marketed disulfide cyclic peptide also 
containing two D-amino acids)91 in kidney and liver, metabolites of 
radiolabeled octreotide were shown to be decyclized (linear) 
products by reduction of the disulfide bond to cysteine and 
fragmented by hydrolysis of the peptide bonds.241 
 
All this data supports the use of the disulfide bond as a tool to 
modulate the stability of the polymyxin scaffold, facilitate 
metabolization and reduce accumulation in kidney.  In fact, the use 
of disulfide bonds in drugs should not be seen as exceptional. There 
are several peptide drugs in the market containing disulfide bonds, 
such as octreotide, lanreotide or vapreotide (analogs of somatostatin 
that consist of a disulfide cyclic octapeptide), insulin, linaclotide (for 
inflammatory bowel syndrome),  ziconotide (treatment of pain), 
pramlintide (for type II diabetes), atosiban (inhibitor of the hormones 
oxytocin and vasopressin), neseritide (for acute decompensated 
congestive heart failure), romidepsin (anticancer agent used in 
cutaneous T-cell lymphoma), and peginesatide (treatment of anemia 
associated with chronic kidney disease). 
 
Preparation of the analogs was carried out by Fmoc/tBu solid phase 
chemical synthesis. Cyclization by means of disulfide bond formation 
was performed at high dilution conditions in plain water and 
dimethylsulfoxide solvent, with no other reagents. Antibacterial 
activity comparable to polymyxin B was achieved, including resistant 
and multi-drug resistant strains.   Analogs 38 and 39 yielded both MIC 
of 2 and 4 μg/mL, respectively against E. coli (vs 1 μg/mL for 
polymyxin B), 1 μg/mL against P. aeruginosa (vs 2  μg/mL, polymyxin 
B). Against resistant strains, Analogs 38 and 39 yielded both MIC of 
0.5 and 0.5-1 μg/mL, respectively against E. coli (vs 0.25-0.5 μg/mL 
for polymyxin B) and 0.5-4 μg/mL against P. aeruginosa (vs 1-2  
μg/mL, polymyxin B).91 Whatsmore, analog 39 was also active against 
Gram-positive bacteria S. aureus and Enterococcus faecalis, 
rendering comparable MIC to those of daptomycin and vancomycin. 
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Analog 38 has also demonstrated synergistic and antibiofilm 
activities with imipenem in a imipenen-resistant strain of P. 
aeruginosa.242 Finally, an in vivo acute toxicity test by subcutaneous 
administration performed on CD-1 mice with analog 38, the LD50 
obtained (283 mg/kg) was clearly superior to the one reported for 
polymyxin B (59.5 mg/kg).91  Further in vivo tests (pharmacokinetic 
studies, full toxicity and efficacy) are ongoing and will be reported in 
due course. 
 
12. Conclusions and Perspectives 
 
The emergence of multi-drug resistant Gram-negative bacteria will 
need of all efforts (antimicrobial chemical design, medicinal 
chemistry, microbiology, pharmacology, development, clinical 
studies, rational use of antibiotics) to control this new health 
challenge. 
 
The research and development of alternative antimicrobial agents is 
a plausible option to tackle the resistance problem and the 
“antibiotic discovery void” since the late 1980s. Unfortunately, in the 
field of polymyxins, only a single candidate, CB-182,804 has 
progressed to a clinical phase but was finally discontinued. Recently, 
a new polymyxin molecule, SPR741, has been announced to proceed 
to clinical phases albeit as a potentiator, not as an antimicrobial per 
se.227 Hence, much effort and new approaches are still needed.   
 
The design, discovery and development of new chemical entities, 
particularly those with new scaffolds or acting by new mechanism of 
action will certainly play a fundamental role. Furthermore, advances 
in the understanding at the molecular level of the mechanism of 
polymyxin toxicity will provide new insights on how to design new 
molecules with better therapeutic indexes. In this sense, the 
incorporation of metabolism considerations into the drug design 
process is a promising new line. New challenges will rise, though, as 
these new chemical units need to keep a balance between stability 
to reach the target and exert the desired antimicrobial activity in vivo 
and later facilitate metabolization and detoxification of the molecule 
thus preventing unwanted side effects. 
 
In the short run, natural polymyxin B/colistin and colistimethate will 
continue to be used as last-line therapeutic option due to the scarcity 
of antibiotics against MDR Gram-negative bacteria. Nevertheless, 
recent pharmacological progress and understanding of the 
mechanism of action and toxicity in polymyxins provides clinicians 
with valuable information for optimizing their use in patients 
(dosage, combinations, nephrotoxicity, biomarkers).243 Still a large 
amount of work is necessary for instance to clarify the advantage of 
antibiotic combinations with polymyxins. In this sense, clinical trials 
to compare colistin monotherapy and the combination with 
meropenem are in progress.150 
 
We hope that the next generation of polymyxins will become 
satisfactory therapeutic tools for the treatment of infections caused 
by multi-drug resistant bacteria. 
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